Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Medicare PPO Prior Auth Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy N/A

    AmeriHealth Medicare PPO — Utilization Management: Prior Authorization, Step Therapy, Quantity Limits and Clinical Criteria for Selected Drugs (coverage criteria)

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists utilization management rules (prior authorization, step therapy, quantity limits, clinical criteria, age and prescriber restrictions, coverage durations, and exclusions) for specific covered drugs under the AmeriHealth Medicare PPO plan; applies to providers, prescribers, pharmacists, and members.

    Policy Summary
    PayerAmeriHealth
    PolicyCoverage criteria — utilization management for selected drugs (Part D / Medicare PPO)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewOct 17, 2025
    Next Review DateN/A
    Key ActionObtain required prior authorization with documented diagnosis, prior therapy trials, and specialist involvement as specified for the requested drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+products listed
    PA, ST, QLutilization types
    Frequentspecialist prescriber required
    12 mocommon reauth duration
    variablecoverage durations

    Drug-specific Coverage Criteria

    Armodafinil (MAC) Initial Therapy

    Armodafinil for Mycobacterium avium complex (MAC) lung disease is covered when ALL of the following are met:

    Armodafinil (MAC) initial criteria: (1) Diagnosis of Mycobacterium avium complex (MAC) lung disease; (2) Medication is being used as part of a combination antibacterial drug regimen; (3) Patient has not achieved at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy; (4) Member is 18 years of age or older; (5) Prescribed by or in consultation with a pulmonologist or infectious disease specialist.

    Coverage duration: remainder of contract year.

    Narcolepsy, OSAHS, SWSD Criteria

    Stimulant and wakefulness agents (narcolepsy, OSAHS, SWSD) are covered when the indication‑specific criteria below are met:

    Narcolepsy criteria: Diagnosis of narcolepsy confirmed by a sleep study unless the prescriber documents that a sleep study is not feasible.

    Prescribed by or in consultation with a neurologist or sleep specialist; coverage indefinite.

    Policy Summary
    PayerAmeriHealth
    PolicyCoverage criteria — utilization management for selected drugs (Part D / Medicare PPO)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewOct 17, 2025
    Next Review DateN/A
    Key ActionObtain required prior authorization with documented diagnosis, prior therapy trials, and specialist involvement as specified for the requested drug.
    SourceLink
    On This Page
    Drug-specific Coverage CriteriaCodes and Numeric ThresholdsPrior Authorization, Documentation, and Step TherapyInitial Authorization RequirementsReauthorization / Continuing TherapyStep Therapy Rules and Required TrialsQuantity and Duration LimitsSite of Care and Part B/Part D NotesPolicy BackgroundKey Definitions and Diagnostic Criteria
    OSAHS criteria: Diagnosis of obstructive sleep apnea/hypopnea syndrome confirmed by a sleep study unless not feasible; sleep study documents ≥5 obstructive respiratory events per hour and member has qualifying symptoms (e.g., daytime sleepiness, unrefreshing sleep, loud snoring, witnessed apneas).>=5 events/hr

    Prescribed by or in consultation with a neurologist or sleep specialist; coverage indefinite.

    Shift Work Sleep Disorder (SWSD): Either: (a) symptoms of excessive sleepiness or insomnia for ≥3 months associated with a work schedule that overlaps normal sleep period, OR (b) sleep study demonstrating disturbed chronobiologic rhythmicity; documentation that no other medical/mental disorder explains symptoms required.>=3 months

    Prescribed by or in consultation with a neurologist or sleep specialist; coverage indefinite.

    TD and CHD Criteria

    Tardive dyskinesia (TD) and chorea due to Huntington disease (CHD) are covered when the following initial and continuation conditions are met:

    Tardive Dyskinesia (initial): (1) Diagnosis of tardive dyskinesia; (2) Documentation that symptoms persist despite a trial of dose reduction, tapering, or discontinuation of the offending medication OR documentation that the member is not a candidate for such a trial.

    Prescribed by or in consultation with a neurologist or psychiatrist; initial coverage 3 months.

    Tardive Dyskinesia (reauthorization): Positive clinical response to therapy is required for reauthorization.

    Reauthorization: indefinite if response documented.

    Chorea - Huntington's Disease: Diagnosis of chorea associated with Huntington's disease.

    Prescribed by or in consultation with a neurologist or psychiatrist; coverage indefinite.

    CAYSTON CF Criteria

    CAYSTON (aztreonam) for cystic fibrosis is covered when ALL of the following are met:

    CAYSTON initial: (1) Diagnosis of cystic fibrosis; (2) Evidence of Pseudomonas aeruginosa in the lungs; (3) Susceptibility results showing the Pseudomonas aeruginosa is sensitive to aztreonam; (4) FEV1 between 25% and 75% predicted; (5) Member is 7 years of age or older; (6) Prescribed by or in consultation with a pulmonologist, infectious disease specialist, or CF care center specialist.FEV1 25-75%

    Coverage duration: remainder of contract year.

    CAYSTON reauthorization: Evidence of Pseudomonas aeruginosa in the lungs and documentation of positive clinical response to therapy (e.g., improved FEV1).

    CHOLBAM BASD/PD Criteria

    CHOLBAM is covered for bile acid synthesis disorders and select peroxisomal disorders when all listed criteria are met:

    Bile Acid Synthesis Disorder (BASD) initial: Diagnosis of bile acid synthesis disorder due to a single enzyme defect; prescribed by a hepatologist, gastroenterologist, medical geneticist, or specialist treating inborn errors of metabolism.

    Initial coverage 3 months; reauthorization indefinite with documentation of improved liver function tests.

    Peroxisomal disorder (PD) initial: Diagnosis of a peroxisomal disorder used as adjunctive treatment in patients with manifestations of liver disease, steatorrhea, or complications from decreased fat‑soluble vitamin absorption; prescribed by the same specialists as above.

    Initial coverage 3 months; reauthorization indefinite.

    Biologic and Cardiac Agent Criteria

    Biologic and selected cardiac agents are covered when indication‑specific prior therapy and prescriber requirements are met:

    Biologics (example: CIMZIA, COSENTYX): Diagnosis per indication AND inadequate response or intolerance to the specified prior therapies (commonly trials of one or two listed biologic/targeted agents or conventional DMARDs as specified for each indication).

    Prescribed by or in consultation with the specialist appropriate to the indication (rheumatologist, dermatologist, gastroenterologist); concurrent use with other biologic DMARDs or TNF antagonists is excluded.

    Corlanor (ivabradine) — chronic heart failure: Diagnosis of chronic heart failure with left ventricular ejection fraction ≤35% AND sinus rhythm with resting heart rate ≥70 bpm AND clinically stable for ≥4 weeks on an optimized regimen including at least two of the specified therapies (beta blocker, ACEi/ARB, SGLT2 inhibitor, MRA) or documented intolerance.LVEF <=35%; HR >=70 bpm

    Prescribed by or in consultation with a cardiologist; coverage indefinite.

    Dalfampridine (MS) Criteria

    Dalfampridine (Ampyra) for multiple sclerosis is covered when the following are met:

    Dalfampridine initial: Diagnosis of multiple sclerosis with difficulty walking; prescriber is a neurologist; exclusion for history of seizure or moderate to severe renal impairment (CrCl ≤50 mL/min).CrCl >50 mL/min

    Coverage remainder of contract year; reauthorization requires documentation of improved walking speed.

    Deferasirox CIO/NTDT Criteria

    Deferasirox (for NTDT and transfusional iron overload) covered when the condition‑specific criteria are met:

    NTDT initial: Diagnosis of chronic iron overload due to non‑transfusion‑dependent thalassemia (NTDT); liver iron concentration (LIC) ≥5 mg Fe/g dw; serum ferritin >300 mcg/L with consistent values (at least two values within the prior two months).LIC >=5 mg Fe/g dw; ferritin >300 mcg/L

    Age ≥10 years for NTDT; initial coverage 3 months; continuation requires decreased serum ferritin or reduction in LIC; exclusion if GFR <40 mL/min/1.73m2 or platelets <50,000/mcL.

    CIO‑BT initial: Diagnosis of chronic iron overload due to transfusional hemosiderosis (CIO‑BT); serum ferritin consistently >1000 mcg/L (two values within prior two months).ferritin >1000 mcg/L

    Age ≥2 years for CIO‑BT; initial 3 months; continuation 6 months with decreased ferritin required; exclusion if GFR <40 mL/min/1.73m2 or platelets <50,000/mcL.

    DOPTELET Criteria

    DOPTELET (avatrombopag) coverage is indication‑specific for chronic liver disease (procedure prophylaxis) and chronic ITP:

    DOPTELET for CLD (procedure): Diagnosis of chronic liver disease with baseline platelet count less than 50,000/mcL and member scheduled to undergo a procedure.Platelets <50,000/mcL

    Coverage duration 1 month; Part B prerequisite may apply; prescriber specialty required.

    DOPTELET for ITP (initial): Diagnosis of chronic immune thrombocytopenia with baseline platelet count less than 30,000/mcL AND inadequate response or inability to tolerate one of corticosteroids, immunoglobulins, splenectomy, or rituximab.Platelets <30,000/mcL

    Prescriber: hematologist/oncologist; coverage 12 months; reauthorization requires positive clinical response (platelet increase sufficient to avoid clinically important bleeding).

    DUPIXENT Indication-specific Criteria

    DUPIXENT (dupilumab) is covered by indication when the specific diagnostic and prior‑therapy criteria below are met:

    Atopic Dermatitis (AD) initial: Diagnosis of moderate‑to‑severe AD with inadequate response or intolerance to one topical therapy (medium‑potency+ steroid, topical tacrolimus, topical pimecrolimus, or crisaborole).

    Concurrent biologic therapy is an exclusion; prescriber: dermatologist/allergist/immunologist; coverage indefinite.

    Asthma initial: Either oral corticosteroid‑dependent asthma OR blood eosinophils ≥150 cells/µL at baseline (or ≥300 cells/µL within past 12 months) AND at least one of: ≥1 exacerbation requiring systemic corticosteroids in past 12 months, prior intubation, or asthma‑related hospitalization; AND to be used in addition to medium‑high dose ICS plus one additional controller.Eosinophils >=150 or >=300

    Prescriber: allergist/immunologist/pulmonologist; coverage specified per indication.

    CRSwNP initial: Diagnosis of chronic rhinosinusitis with nasal polyposis and concurrent intranasal corticosteroid use.

    Prescriber: allergist/immunologist/ENT; coverage per policy.

    EoE initial: Diagnosis of eosinophilic esophagitis with symptoms of esophageal dysfunction, ≥15 intraepithelial eosinophils per HPF, exclusion of other causes, member weight ≥15 kg, and inadequate response or intolerance to an 8‑week trial of specified therapies.>=15 eosinophils/HPF; weight >=15 kg

    Prescriber: gastroenterologist/allergist/immunologist; coverage per policy.

    ITP (Initial)

    Chronic immune thrombocytopenia (ITP) initial therapy is covered when ALL of the following are met:

    ITP Initial: (1) Baseline platelet count less than 30,000/mcL; (2) Inadequate response or inability to tolerate one of: corticosteroids, immunoglobulins, splenectomy, or rituximab; (3) Prescribed by or in consultation with a hematologist/oncologist.platelets <30,000/mcL

    Coverage duration 12 months; reauthorization requires positive clinical response.

    CLD - Procedure

    Chronic liver disease (CLD) procedural platelet support is covered when ALL of the following are met:

    CLD Procedural: (1) Diagnosis of chronic liver disease; (2) Baseline platelet count less than 50,000/mcL and member is scheduled to undergo a procedure.platelets <50,000/mcL

    Coverage duration 1 month; prescriber specialty as required by policy.

    Dermatology / Pulmonology / GI Initial Criteria

    Initial therapy criteria for dermatology, pulmonary, and GI biologic indications (examples: AD, asthma, CRSwNP, EoE, bullous pemphigoid) — covered when ALL of the following are met:

    Atopic Dermatitis (AD) Initial: Diagnosis of moderate‑to‑severe AD with inadequate response or intolerance to one topical therapy (medium potency+ steroid, topical tacrolimus, topical pimecrolimus, or crisaborole).age limits apply

    Age: AD ≥6 months; prescriber: dermatologist/allergist/immunologist; coverage indefinite for AD.

    Asthma Initial: Either oral corticosteroid‑dependent asthma OR blood eosinophils ≥150 cells/µL at baseline (or ≥300 within past 12 months); AND at least one of: ≥1 exacerbation requiring systemic corticosteroids in past 12 months OR prior intubation OR asthma‑related hospitalization in past 12 months; AND to be used in addition to medium‑high dose ICS and one additional controller.age ≥6 years

    Prescriber: allergist/immunologist/pulmonologist; initial coverage 12 months.

    CRSwNP Initial: Diagnosis of CRSwNP with concurrent intranasal corticosteroid use and inadequate response to intranasal steroids as specified.age ≥12 years

    Prescriber: allergist/immunologist/ENT; coverage 12 months.

    EoE Initial: Diagnosis of eosinophilic esophagitis with symptoms of esophageal dysfunction; ≥15 intraepithelial eosinophils/HPF; exclusion of other causes; member weight ≥15 kg; inadequate response or intolerance to an 8‑week trial of PPI or topical esophageal corticosteroids.>=15 eosinophils/HPF

    Prescriber: gastroenterologist/allergist/immunologist; coverage 12 months.

    Emgality - Migraine

    Emgality (galcanezumab) for migraine prophylaxis is covered when ONE of the following is met:

    Episodic migraine — initial: Diagnosis of episodic migraine (4–14 headache days/month) AND inadequate response or inability to tolerate a 4‑week trial of or contraindication to TWO listed prophylactic medications (e.g., topiramate, divalproex, beta‑blockers, TCAs, SNRIs, candesartan).4-14 headache days/month

    Age ≥18; prescriber: neurologist/headache specialist; initial coverage 6 months; reauth 12 months with documented response.

    Chronic migraine — initial: Diagnosis of chronic migraine (≥15 headache days/month) AND inadequate response or inability to tolerate a 4‑week trial of or contraindication to TWO listed prophylactic medications.>=15 headache days/month

    Age ≥18; initial coverage 6 months; reauth 12 months with documentation of response (reduction in headache days).

    Entyvio Pen - UC/CD

    ENTYVIO® (vedolizumab) subcutaneous maintenance (Entyvio Pen) for UC and CD is covered when ALL of the following are met:

    Ulcerative Colitis Initial: Diagnosis of moderately to severely active ulcerative colitis AND inadequate response or inability to tolerate two of: adalimumab, ustekinumab, upadacitinib, tofacitinib, risankizumab OR documentation that trials are inappropriate; OR used as maintenance following IV induction or the member is established on Entyvio IV.age >=18

    Prescriber: gastroenterologist; coverage indefinite.

    Crohn's Disease Initial: Diagnosis of moderately to severely active Crohn's disease AND inadequate response or inability to tolerate TWO of: adalimumab, ustekinumab, risankizumab, upadacitinib OR documentation that trials are inappropriate; OR used as maintenance following IV induction or member established on Entyvio IV.age >=18

    Prescriber: gastroenterologist; coverage indefinite.

    Epidiolex - Epileptic Syndromes

    EPIDIOLEX (cannabidiol) for certain epileptic syndromes is covered when ALL of the following are met:

    Dravet Syndrome Initial: Diagnosis of Dravet syndrome AND inadequate response or intolerance to one of clobazam, valproic acid, or topiramate; baseline CBC, LFTs and total bilirubin prior to initiating; concurrent use with additional antiepileptics as required.age >=1 year

    Prescriber: neurologist; coverage indefinite; continuation approved with documentation of benefit.

    Lennox‑Gastaut Syndrome Initial: Diagnosis of Lennox‑Gastaut syndrome AND inadequate response or intolerance to one of clobazam, valproic acid, or topiramate; baseline CBC, LFTs and total bilirubin prior to initiating; concurrent antiepileptic therapy required.age >=1 year

    Prescriber: neurologist; coverage indefinite.

    Tuberous Sclerosis Complex Initial: Diagnosis of TSC with seizures AND concurrent use with additional antiepileptics; baseline CBC, LFTs and total bilirubin prior to initiating therapy.age >=1 year

    Prescriber: neurologist; coverage indefinite; continuation approved.

    Fasenra - Severe Asthma / EGPA

    Fasenra (benralizumab) for severe eosinophilic asthma and EGPA is covered when ALL of the following are met:

    Severe Asthma Initial: Diagnosis of severe eosinophilic asthma with eosinophil thresholds (≥150 cells/µL if OCS‑dependent or ≥300 cells/µL) AND at least one exacerbation requiring systemic corticosteroids or prior intubation or hospitalization in past 12 months AND current treatment with high‑dose ICS plus another controller or maximally‑dosed ICS/LABA combination.eosinophils >=150 or >=300

    Age ≥6 years; prescriber: pulmonologist or allergy/immunology; coverage 12 months.

    EGPA Initial: Diagnosis of eosinophilic granulomatosis with polyangiitis with relapse or refractory disease to standard therapy AND currently receiving corticosteroid therapy unless contraindicated.age >=18 years

    Prescriber: pulmonologist, rheumatologist, or allergy/immunology; coverage 12 months; reauth requires positive clinical response.

    Galafold - Fabry Disease

    GALAFOLD (migalastat) for Fabry disease is covered when ALL of the following are met:

    Fabry Disease Initial: Member has an amenable GLA (GLA/GLA‑variant) based on in vitro assay data; will not be used in combination with enzyme replacement therapy for Fabry disease.age >=18

    Prescriber: clinical genetics specialist or nephrologist; initial coverage 6 months; reauthorization indefinite with documented clinical response.

    Growth Hormone Therapies

    Growth hormone therapies are covered for pediatric and other growth indications when ALL required diagnostic criteria are met:

    Growth Failure in Children (GFC) - Initial: Diagnosis of growth hormone deficiency confirmed by diagnostic criteria such as height >2.0 SD below midparental height OR >2.25 SD below population mean, growth velocity >2 SD below mean, delayed skeletal maturation >2 SD below mean; documentation of bone age and abnormal response on provocative testing required.as stated

    Prescriber: endocrinologist; initial and continuation coverage 12 months with annual re‑evaluation.

    SGA / ISS / GF‑CKD / Syndromic growth failure: Specific diagnostic confirmations per indication (e.g., SGA with no catch‑up growth by 2–4 years; ISS height SDS ≤‑2.25; GF‑CKD without transplant) with required documentation such as bone age, growth velocity, and provocative testing when indicated.ISS height SDS <= -2.25

    Prescriber: endocrinologist; coverage 12 months, annual re‑evaluation for continuation and response metrics required.

    Growth Failure in Children (GFC) - Initial

    Growth failure in children (GFC) — initial diagnostics and supporting tests required:

    GFC diagnostic criteria: (A) Diagnosis of growth hormone deficiency confirmed by one of: (I) Height >2.0 SD below midparental height OR >2.25 SD below population mean; (II) Growth velocity >2 SD below mean; (III) Delayed skeletal maturation >2 SD below mean.as stated

    Utilize age‑ and gender‑appropriate growth charts.

    Supporting tests: (B) Documentation of bone age and (C) abnormal response from provocative testing (e.g., insulin‑induced hypoglycemia, levodopa, clonidine).as stated

    Prescriber: endocrinologist; initial coverage 12 months.

    Small for Gestational Age (SGA) - Initial

    Small for gestational age (SGA) initial criteria:

    SGA criteria: (A) Diagnosis of small for gestational age (SGA); (B) Clinical documentation of no catch‑up growth by 2 to 4 years of age.as stated

    Prescriber: endocrinologist; coverage per policy.

    Growth Failure Associated with Chronic Kidney Disease (GF-CKD) - Initial

    Growth failure associated with chronic kidney disease (GF‑CKD) initial criteria:

    GF-CKD: Diagnosis of growth failure associated with chronic kidney disease; prescriber may be endocrinologist or nephrologist.

    Initial coverage per policy; annual re‑evaluation required for continuation.

    Growth Hormone Gene Deletion (GHGD) and Severe Primary IGF-1 Deficiency (PIGF-1D)

    Growth hormone gene deletion (GHGD) and severe primary IGF‑1 deficiency (PIGF‑1D) are covered when ALL of the following are met:

    GHGD initial: Diagnosis of growth hormone gene deletion with development of neutralizing antibodies to growth hormone; member age ≥2 years; prescribed by an endocrinologist.

    Initial and continuation coverage 12 months; annual re‑evaluation and documented increase in growth velocity required for continuation.

    PIGF-1D initial: Diagnosis of severe primary IGF‑1 deficiency AND height SDS ≤‑3.0 AND basal IGF‑1 SDS ≤‑3.0 with normal or elevated growth hormone; member age ≥2 years; prescriber endocrinologist.Height SDS ≤ -3.0; basal IGF-1 SDS ≤ -3.0

    Initial and continuation coverage 12 months; continuation requires documented increase in growth velocity and expected adult height considerations.

    High-dose Opioid Therapy - Initial / Continuing High-dose Opioid Therapy

    High‑dose opioid therapy initial and continuation coverage rules:

    High‑dose Opioid Therapy - Initial: Cancer‑related pain OR chronic non‑cancer pain when BOTH: (1) member is opioid tolerant (example thresholds provided) AND (2) member has been evaluated for non‑opioid prescription pharmacologic treatments prior to initiation of high‑dose opioid therapy.opioid tolerance examples provided

    Coverage duration: remainder of contract year for initial; prior authorization required.

    Continuing high‑dose therapy: (1) Pain associated with cancer OR (2) chronic non‑cancer pain and ALL: (a) pain assessed within last 6 months; (b) clinically meaningful improvement in pain and functioning that outweighs safety risks; (c) member not being treated for substance abuse.Morphine equivalent dose ≥90 mg/day referenced for continuation

    Reauthorization requires documentation of benefit; prior authorization required.

    TOBI PODHALER for Cystic Fibrosis

    TOBI PODHALER for cystic fibrosis is covered when ALL of the following are met:

    TOBI PODHALER CF criteria: (1) Diagnosis of cystic fibrosis; (2) Evidence of Pseudomonas aeruginosa in the lungs; (3) FEV1 between 25% and 80% predicted; (4) Member not colonized with Burkholderia cepacia.FEV1 between 25% and 80%

    Member age ≥6 years; prescribed by pulmonologist/ID/CF specialist; coverage remainder of contract year.

    Kalydeco (ivacaftor) for Cystic Fibrosis

    Kalydeco (ivacaftor) for cystic fibrosis is covered when ALL of the following are met:

    Kalydeco mutation requirement: (1) Diagnosis of cystic fibrosis with documentation of a CFTR mutation responsive to ivacaftor based on clinical and/or in vitro assay data; (2) Mutation documented by an FDA‑cleared CF mutation test with verification by bi‑directional sequencing when recommended.

    Member age criteria per formulation: granules ≥1 month, tablets ≥6 years; prescriber: pulmonologist/CF specialist; coverage indefinite.

    Immune Globulin (GAMUNEX-C) - Part D

    Immune globulin (GAMUNEX‑C) Part D coverage: covered when ONE of multiple specified indications is met:

    Autoimmune mucocutaneous blistering disease: Diagnosis (e.g., pemphigus vulgaris, bullous pemphigoid) AND inadequate response or inability to tolerate conventional therapy OR rapidly progressive disease in conjunction with conventional therapy.

    Prescriber: specialist with expertise in immune globulin therapy; other autoimmune, infectious, transplant‑related indications enumerated in policy.

    Chronic ITP: Chronic immune thrombocytopenia meeting criteria including inadequate response/intolerance to corticosteroids, duration >6 months, platelets persistently <20,000/µL.platelets <20,000/µL

    Prescriber with expertise required; coverage per indication.

    Mifepristone for Hyperglycemia in Cushing Syndrome

    Mifepristone for hyperglycemia in endogenous Cushing syndrome is covered when ALL of the following are met:

    HCS criteria: (1) Hyperglycemia secondary to endogenous Cushing syndrome in an adult; (2) Member has type 2 diabetes or glucose intolerance; (3) Member failed surgery or is not a surgical candidate.

    Prescribed by or in consultation with an endocrinologist; exclusion: pregnancy; coverage indefinite.

    Livtencity for Cytomegalovirus (CMV)

    LIVTENCITY (letermovir) for cytomegalovirus (CMV) is covered when ALL of the following are met:

    CMV criteria: (1) Diagnosis of CMV infection/disease; (2) Member is recipient of hematopoietic stem cell transplant or solid organ transplant; (3) Inadequate response to a minimum 2‑week course of IV ganciclovir or oral valganciclovir or IV foscarnet or IV cidofovir at appropriate dose OR intolerance to those agents; (4) Member weight ≥35 kg.weight >=35 kg

    Member age ≥12 years; prescriber: transplant/infectious disease/oncology specialist; coverage duration 8 weeks.

    Modafinil indications (narcolepsy, OSAHS, SWSD, MS fatigue)

    Modafinil and related sleep disorder stimulant agents are covered for narcolepsy, OSAHS, SWSD when ALL of the following are met:

    Narcolepsy: Diagnosis of narcolepsy confirmed by sleep study unless prescriber justifies that a sleep study is not feasible.

    Prescribed by or in consultation with a neurologist or sleep specialist; coverage indefinite.

    OSAHS: Diagnosis of obstructive sleep apnea/hypopnea syndrome confirmed by sleep study or documented justification if not feasible; sleep study documents ≥5 obstructive respiratory events/hour and at least one qualifying symptom.>=5 events/hour

    Prescribed by or in consultation with a neurologist or sleep specialist; coverage indefinite.

    SWSD: Symptoms of excessive sleepiness or insomnia for ≥3 months associated with work schedule OR sleep study demonstrating disturbed chronobiologic rhythmicity, with documentation that no other medical or mental disorder explains the symptoms.>=3 months

    Prescribed by or in consultation with neurologist or sleep specialist; coverage indefinite.

    Cytomegalovirus (CMV) — Part of antiviral coverage

    CMV antiviral coverage (part of antiviral coverage) — initial criteria:

    CMV initial: (1) Diagnosis of CMV infection/disease AND (2) Recipient of hematopoietic stem cell transplant or solid organ transplant AND (3) Inadequate response to ≥2 weeks of listed antivirals (IV ganciclovir, oral valganciclovir, IV foscarnet, IV cidofovir) or inability to tolerate them at appropriate dose AND (4) Member weight ≥35 kg.

    Coverage duration 8 weeks; prescriber transplant/infectious disease/oncology specialist required.

    Nexletol/Nexlizet (bempedoic acid ± ezetimibe) — HeFH/Primary hyperlipidemia and CVD risk

    Nexletol / Nexlizet (bempedoic acid ± ezetimibe) coverage for HeFH or primary hyperlipidemia with CVD risk:

    Indication: Diagnosis of heterozygous familial hypercholesterolemia (HeFH) OR primary hyperlipidemia.
    Statin/intolerance requirement: Either LDL‑C ≥70 mg/dL after ≥8 weeks of statin therapy with ongoing maximally tolerated statin OR documented statin intolerance meeting specified criteria (rhabdomyolysis, CK elevations, hepatotoxicity, etc.).>=8 weeks statin trial

    Ezetimibe adjunct required in many scenarios.

    Ezetimibe requirement: (A) Member has received ≥8–12 weeks of generic ezetimibe as adjunct to maximally tolerated statin OR (B) documented contraindication or intolerance to ezetimibe.>=8 weeks

    Initial duration 6 months; continuation 12 months; LDL‑C thresholds per policy.

    Part D medically necessary criteria for certain oncology/supportive drugs

    Part D medically necessary criteria for certain oncology/supportive drugs:

    Part D inclusion: Approval if ANY of the following are met: (1) drug is FDA‑approved for the requested indication/regimen; (2) indication/regimen is NCCN Category 1 or 2A; (3) supportive AHFS‑DI or Clinical Pharmacology narrative; (4) Micromedex Class I/IIa/IIb support; (5) Lexi‑Drugs off‑label evidence level A; or (6) supported by peer‑reviewed medical literature per Medicare criteria.

    Coverage duration: indefinite; subject to Part B vs Part D review where applicable.

    GLP-1 and GLP-1-like agents for Type 2 Diabetes (class requirement example)

    GLP‑1 and GLP‑1‑like agents for type 2 diabetes — class requirement example:

    Diabetes documentation: Medical records confirming diagnosis of type 2 diabetes mellitus (e.g., A1C ≥6.5%, FPG ≥126 mg/dL, or 2‑hr OGTT ≥200 mg/dL).lab values as listed
    Prior therapy requirement: Inadequate response or intolerance to a minimum 90‑day supply of two preferred brand GLP‑1 agents (e.g., Ozempic, Trulicity, Rybelsus, Mounjaro, Victoza).>=90 days each

    Prescriber and documentation requirements apply; coverage indefinite.

    Posaconazole — treatment and prophylaxis

    Posaconazole for invasive fungal disease treatment or prophylaxis is covered when ALL of the following are met:

    TAI treatment: Diagnosis of treatment‑requiring invasive aspergillosis (TAI) and prescribed by or in consultation with appropriate specialist.

    Age ≥13 years for treatment; coverage remainder of contract year as specified.

    Prophylaxis AI/CI: Severely immunocompromised patient for prophylaxis of invasive Aspergillus or Candida infection after inadequate response or intolerance to voriconazole.

    Age ≥2 years for prophylaxis; prescriber: ID/transplant/oncology specialist or part of chemotherapy prophylaxis protocol.

    Nucala (mepolizumab) — multiple eosinophilic indications

    Nucala (mepolizumab) is covered for multiple eosinophilic indications when indication‑specific criteria are met:

    Severe eosinophilic asthma (initial): Diagnosis of severe eosinophilic asthma with blood eosinophils ≥150 cells/µL at initiation (or ≥300 cells/µL within past 12 months) AND at least two exacerbations requiring systemic steroids in past 12 months or prior intubation or hospitalization AND current treatment with high‑dose ICS plus another controller or maximally‑dosed ICS/LABA.eosinophils >=150 or >=300

    Prescriber: pulmonologist or allergy/immunology; initial and reauth age ≥6; coverage 12 months.

    HES (initial): Diagnosis of hypereosinophilic syndrome (HES) for ≥6 months with secondary causes excluded, FIP1L1‑PDGFRA negative, pretreatment eosinophils ≥1000 cells/µL AND inadequate response or intolerance to corticosteroids or cytotoxic/immunosuppressive therapy.>=1000 cells/µL

    Age ≥12 for HES; specialist prescriber required; coverage 12 months.

    EGPA: Diagnosis of eosinophilic granulomatosis with polyangiitis relapsed or refractory to standard therapy and currently receiving corticosteroids.

    Prescriber: rheumatologist; reauth requires positive clinical response.

    CRSwNP: Diagnosis of chronic rhinosinusitis with nasal polyps with inadequate response to ≥2 months of intranasal corticosteroid and used with intranasal steroid.>=2 months

    Prescriber: appropriate specialist; age and coverage duration per policy.

    COPD with Type‑2 inflammation: Diagnosis of COPD with Type‑2 inflammation (blood eosinophils ≥150 baseline or ≥300 in last 12 months), receiving triple therapy (ICS+LAMA+LABA) or LAMA+LABA if ICS contraindicated, and ≥2 exacerbations requiring systemic steroids or hospitalization in past 12 months.eosinophils >=150 or >=300

    Prescriber: pulmonologist; coverage 12 months.

    Tavaborole — onychomycosis

    Tavaborole for toenail onychomycosis is covered when ALL of the following are met:

    Onychomycosis diagnostic criteria: Diagnosis of toenail onychomycosis due to Trichophyton rubrum or T. mentagrophytes confirmed by positive KOH, culture, or histology AND condition causes debility or disruption of activities of daily living.
    Prior therapy requirement: Inadequate response or inability to tolerate BOTH oral generic terbinafine and either oral generic itraconazole OR topical generic ciclopirox.

    Coverage duration 1 year; prescriber and documentation requirements per policy.

    NUPLAZID (pimavanserin) — Parkinson disease psychosis

    Nuplazid (pimavanserin) for Parkinson disease psychosis is covered when ALL of the following are met:

    HDPDP criteria: Diagnosis of hallucinations and delusions of Parkinson disease psychosis AND inadequate response or inability to tolerate quetiapine or clozapine.

    Prescriber: neurologist or psychiatrist; coverage indefinite; exclusion for prolonged QT, congenital long QT syndrome, or Torsades de pointes as applicable.

    Nurtec (rimegepant) — acute and preventive migraine

    Nurtec (rimegepant) — acute and preventive migraine coverage criteria:

    Acute treatment (AM): Diagnosis of migraine with or without aura in adults with <15 headache days/month AND inadequate response or inability to tolerate one generic triptan.<15 days/month

    Prescriber: neurologist/headache specialist or certified pain specialist; initial coverage 6 months; reauth 12 months.

    Preventive treatment (MP): Diagnosis of episodic migraine (4–18 migraine days/month) AND inadequate response or inability to tolerate a 4‑week trial of TWO listed prophylactic medications.4–18 days/month

    Prescriber specialty required; initial coverage 6 months; reauth 12 months with documented response.

    OFEV (nintedanib) — fibrosing interstitial lung disease indications

    OFEV (nintedanib) for fibrosing interstitial lung disease indications is covered when ALL of the following are met:

    IPF: Diagnosis of idiopathic pulmonary fibrosis confirmed by high‑resolution CT or biopsy; prescribed by or in consultation with a pulmonologist.

    Coverage 12 months; reauth requires stabilization and liver enzyme monitoring per policy.

    SSc‑ILD: Diagnosis of systemic sclerosis‑associated interstitial lung disease confirmed by HRCT or biopsy; prescribed by pulmonologist.

    Coverage 12 months.

    Chronic fibrosing ILD with progressive phenotype: HRCT demonstrating ≥10% lung volume with fibrotic features AND evidence of progressive phenotype (decline in FVC or worsening symptoms).>=10% lung volume

    Prescriber: pulmonologist; reauth requires stabilization and liver enzyme limits.

    Olumiant (baricitinib) — RA and Alopecia Areata

    Olumiant (baricitinib) coverage for RA and alopecia areata is met when ALL of the following are satisfied:

    Rheumatoid arthritis (RA): Diagnosis of RA AND inadequate response or intolerance to two of the specified agents (e.g., adalimumab, Enbrel, Rinvoq, Xeljanz) OR documentation that trials are inappropriate.

    Prescribed by or in consultation with a rheumatologist; coverage indefinite.

    Alopecia areata (AA): Diagnosis of alopecia areata with ≥50% scalp hair loss and other causes ruled out AND inadequate response or inability to tolerate one previous AA treatment.>=50% scalp hair loss

    Prescribed by or in consultation with a dermatologist; coverage indefinite.

    Opipza (cariprazine) — psychiatric indications

    Opiprazole (cariprazine) coverage for psychiatric indications is met when ALL of the following are satisfied:

    Schizophrenia: Diagnosis of schizophrenia AND inadequate response or inability to tolerate aripiprazole and another generic formulary antipsychotic.

    Coverage indefinite; continuation allowed.

    Adjunctive MDD: Diagnosis of major depressive disorder as adjunctive treatment AND inadequate response or inability to tolerate aripiprazole and quetiapine.

    Coverage indefinite.

    Autistic disorder irritability: Diagnosis of irritability associated with autistic disorder AND inadequate response or inability to tolerate aripiprazole.

    Coverage indefinite.

    Tourette's disorder: Diagnosis of Tourette's disorder AND inadequate response or inability to tolerate aripiprazole.

    Coverage indefinite.

    General PA coverage criteria

    General prior authorization coverage criteria — approve when ANY of the following evidence standards are met:

    General evidence standards: Approve if any one of: (A) FDA‑approved indication/regimen requested; (B) NCCN Drugs & Biologics Compendium Category 1 or 2A; (C) supportive AHFS‑DI or Clinical Pharmacology narrative; (D) Micromedex Class I/IIa/IIb recommendation; (E) Lexi‑Drugs off‑label evidence level A; or (F) supported by peer‑reviewed medical literature per Medicare criteria.

    Applies across listed products; subject to Part B vs Part D determination as noted.

    PAH Initial Therapy / PAH Continuation Therapy

    Pulmonary arterial hypertension (PAH) initial and continuation authorization requirements:

    PAH initial: (1) Diagnosis of PAH WHO Group I with NYHA Functional Class II–IV; (2) Diagnostic confirmation by right‑heart catheterization or echocardiography; (3) Mean pulmonary artery pressure ≥25 mm Hg at rest (or >30 mm Hg with exertion).mPAP >=25 mm Hg

    Prescribed by or in consultation with cardiologist or pulmonologist; initial coverage typically 6 months.

    PAH continuation: Stabilization or improvement as evaluated by a cardiologist or pulmonologist is required for reauthorization.

    Continuation coverage duration: 12 months.

    Lipid-lowering agent criteria

    Lipid‑lowering agent criteria (HLA/ASCVD/HoFH) — initial and continuation rules:

    HLA/ASCVD initial: Diagnosis of hyperlipidemia or ASCVD AND LDL‑C ≥70 mg/dL after ≥8‑week trial of at least moderate‑intensity statin therapy OR documented statin intolerance (per specified lab/clinical criteria).LDL‑C >=70 mg/dL after ≥8‑week statin trial

    Initial duration commonly 6 months; continuation 12 months; documentation of LDL and prior statin trial required.

    HoFH initial: (1) Diagnosis of homozygous familial hypercholesterolemia (HoFH); (2) Untreated LDL‑C >400 mg/dL; (3) Member is receiving other lipid‑lowering therapy (e.g., statin, ezetimibe) and drug is not used with lomitapide (Juxtapid).LDL‑C >400 mg/dL

    Initial coverage 6 months; reauth requires positive clinical response and continued use of other lipid‑lowering therapy.

    Osteoporosis therapy

    Osteoporosis therapy (agents subject to Part D review) — initial criteria:

    Osteoporosis initial: Diagnosis of osteoporosis confirmed by T‑score ≤‑2.5 OR history of osteoporotic fracture OR multiple risk factors, AND inadequate response or intolerance to at least one other osteoporosis medicine OR severely deteriorated condition or documented moderate‑severe renal insufficiency (GFR ≤30–35 mL/min).T-score <= -2.5

    Coverage duration: 12 months.

    PROMACTA criteria set

    PROMACTA (eltrombopag) criteria — covered when INDICATION‑specific requirements are met:

    PROMACTA indications: Indicated uses include ITP with baseline platelets <30,000/mcL and inadequate response or intolerance to corticosteroids/IVIG/splenectomy; severe aplastic anemia in combination with standard immunosuppressive therapy under defined hematologic thresholds; chronic HCV‑associated thrombocytopenia under defined conditions.platelets <30,000/mcL for ITP

    Prescribed by or in consultation with hematologist/oncologist; coverage durations vary by indication; reauth requires platelet response.

    CFTR modulator criteria

    CFTR modulator criteria (example: ORKAMBI) — initial requirements:

    CFTR modulator initial: Diagnosis of cystic fibrosis AND genotype confirmation (e.g., homozygous F508del) where required; if genotype unknown, use FDA‑cleared test to detect F508del on both alleles.genotype: homozygous F508del

    Prescribed by or in consultation with pulmonologist or CF care specialist; coverage indefinite.

    Sirturo MDR-TB

    SIRTURO (bedaquiline) for pulmonary MDR‑TB initial coverage is met when ALL criteria are satisfied:

    MDR‑TB initial: (1) Diagnosis of multi‑drug resistant tuberculosis (MDR‑TB); (2) Member weight ≥15 kg (applies to ages 5 to <18); (3) Used in combination with ≥3 other drugs shown susceptible in vitro OR, if susceptibility unknown, with ≥4 likely susceptible drugs; (4) Administered by directly observed therapy (DOT).

    Prescriber: infectious disease specialist or pulmonologist; coverage duration 24 weeks.

    Vowst - Prevention of recurrent CDI

    Vowst for prevention of recurrent C. difficile infection is covered when ALL of the following are met:

    Vowst PCDI criteria: (1) Diagnosis of recurrent C. difficile infection defined by ≥3 loose stools/day for at least 2 consecutive days and a positive stool test for C. difficile toxin or toxigenic C. difficile; (2) History of two or more recurrent CDI episodes within 12 months; (3) Completed at least 10 consecutive days of specified antibiotics (oral vancomycin or fidaxomicin) 2–4 days prior to initiating Vowst; (4) Completed recommended bowel prep the day before and ≥8 hours prior to initiating Vowst; (5) Previous episode is under control (e.g., <3 unformed stools/day for at least 2 consecutive days).

    Member ≥18; prescriber: gastroenterologist or infectious disease specialist; coverage duration 14 days.

    Xifaxan (rifaximin) coverage rules

    Xifaxan (rifaximin) coverage rules — covered when ALL indication‑specific criteria are met:

    Hepatic encephalopathy prophylaxis: Diagnosis of hepatic disease with risk for hepatic encephalopathy AND inadequate response or intolerance to lactulose.

    Coverage indefinite.

    IBS‑D: Diagnosis of irritable bowel syndrome with diarrhea AND inadequate response or inability to tolerate BOTH: (A) one tricyclic antidepressant OR one SSRI AND (B) dicyclomine; member does not exceed three total courses (42 days total).

    Coverage typically 2 weeks per course; exceeding three total courses triggers denial.

    SBBO/SIBO: Diagnosis of small bowel bacterial overgrowth (SBBO/SIBO); documentation of recurrence following successful initial treatment required for reauthorization.

    Initial and reauth courses typically 2 weeks.

    Xolair - Multiple indications

    Xolair (omalizumab) coverage for multiple indications is met when ALL indication‑specific criteria are satisfied:

    Moderate‑to‑severe persistent allergic asthma (PAA): Diagnosis of moderate‑to‑severe persistent allergic asthma; positive skin test or in‑vitro reactivity to a perennial aeroallergen; baseline serum IgE between 30–1300 IU/mL; inadequate response or inability to tolerate high‑dose ICS + LABA.IgE 30–1300 IU/mL

    Member ≥6 years; prescriber: allergist/immunologist or pulmonologist; initial/reauth 12 months; concurrent biologic agents for asthma/allergic conditions excluded.

    Chronic urticaria (CU): Diagnosis of chronic urticaria with inadequate response, contraindication or intolerance to one second‑generation H1 antihistamine at maximally tolerated dose plus listed adjuncts; will be used concurrently with an H1 antihistamine unless contraindicated.

    Member ≥12 years; reauth requires disease re‑evaluation and evidence of improvement.

    IgE‑mediated food allergy (IMFA): Diagnosis or clinical history of IgE‑mediated food allergy or history of severe allergic response/anaphylaxis to foods; used with food allergen avoidance; baseline total IgE ≥30 and ≤1850 IU/mL; dosing per IgE and body weight.>=30 and <=1850 IU/mL

    Reauth requires documentation of positive clinical response; initial/reauth duration 12 months.

    XYREM — Initial therapy

    XYREM (sodium oxybate) for narcolepsy (cataplexy and excessive daytime sleepiness) is covered when ALL of the following are met:

    Cataplexy in narcolepsy (CN) initial: Diagnosis of cataplexy in narcolepsy confirmed by polysomnography (PSG) or multiple sleep latency test (MSLT) OR prescriber justification if sleep study not feasible; prescriber neurologist, psychiatrist, or sleep specialist required.

    Coverage duration 12 months; exclusion: concurrent use of sedative hypnotics and alcohol.

    Excessive Daytime Sleepiness in Narcolepsy (EDSN) initial: Diagnosis of EDSN (Narcolepsy Type 2) confirmed by PSG or MSLT or justified if study not feasible; inadequate response or inability to tolerate modafinil or armodafinil (adult use only).

    Prescriber specialty required; initial/reauth coverage 12 months with documentation of efficacy for reauthorization; exclusion: concurrent sedative hypnotics and alcohol.

    ZTALMY — CDKL5 deficiency / ZURZUVAE — Postpartum depression

    ZTALMY and ZURZUVAE coverage criteria:

    ZTALMY (CDKL5 deficiency) initial/continuation: (1) Diagnosis of CDKL5 deficiency disorder with documented CDKL5 gene mutation; (2) Member is experiencing motor seizures (e.g., bilateral tonic, generalized tonic‑clonic, bilateral clonic, atonic, focal); (3) Inadequate response or inability to tolerate two formulary anticonvulsants (e.g., valproic acid, levetiracetam, lamotrigine); (4) Prescribed by or in consultation with a neurologist.

    Member must be ≥2 years old; coverage indefinite for continuation; documentation required for continuation.

    ZURZUVAE (postpartum depression): (1) Diagnosis of postpartum depression; (2) Inadequate response or inability to tolerate one generic SSRI AND one generic SNRI; (3) Medication will not be used for greater than 14 days.

    Member ≥18 years; coverage duration 14 days.

    Codes and Numeric Thresholds

    Referenced product/catalog entriesmixed
    product listLarge list of oncology and specialty drug product names appears (partial listing in chunks 90-92).
    Covered drug products (listed)mixedCovered
    IBTROZIIBTROZI
    ABIRTEGAABIRTEGA
    ICLUSIGICLUSIG
    AKEEGAAKEEGA
    IDHIFAIDHIFA
    ALECENSAALECENSA
    imatinib mesylate oralimatinib mesylate oral
    ALUNBRIGALUNBRIG
    IMBRUVICAIMBRUVICA
    AUGTYROAUGTYRO
    1–10 of 50
    1/5
    Nephrotic syndrome proteinuria
    ThresholdProteinuria > 3.5 g/24 hours
    Supporting findingPeripheral edema present
    Required prior therapyInadequate response or intolerance to two systemic steroids
    Serum albumin threshold (nephrotic syndrome)
    Serum albumin cutoffSerum albumin < 3 mg/dL
    ContextUsed with proteinuria >3.5 g/24h and peripheral edema for nephrotic syndrome criteria
    Associated requirementInadequate response or intolerance to two systemic steroids
    Mean pulmonary artery pressure
    Resting mPAP>= 25 mm Hg at rest
    Exertional mPAP> 30 mm Hg with exertion
    Required confirmationDiagnosis confirmed by right-heart catheterization or echocardiography
    Episodic migraine frequency
    Episodic migraine frequency4 to 14 headache days per month
    Prior prophylactic trialsInadequate response or intolerance to two 4‑week trials of listed prophylactic medications
    Age/prescriberMember >=18 years; prescriber neurologist/headache specialist or pain specialist
    Chronic migraine frequency
    Chronic migraine frequency>= 15 headache days per month
    Prior prophylactic trialsInadequate response or intolerance to two 4‑week trials of listed prophylactic medications
    Authorization notesInitial coverage typically 6 months; reauthorization 12 months with documentation of response
    Dalfampridine renal contraindication
    Renal contraindicationCrCl <= 50 mL/min (dalfampridine contraindicated)
    Other exclusionHistory of seizure is an exclusion
    PrescriberPrescribed by or in consultation with a neurologist
    FEV1 percent predicted
    CAYSTON FEV1 rangeFEV1 between 25% and 75% predicted
    TOBI PODHALER range (related CF agent)FEV1 between 25% and 80% predicted
    Use contextFEV1 requirement part of CF inhaled antibiotic eligibility and reauthorization assesses improved FEV1
    Left ventricular ejection fraction
    LVEF thresholdLeft ventricular ejection fraction <= 35%
    Required rhythm/HRSinus rhythm with resting heart rate >= 70 bpm for ivabradine eligibility
    PrescriberPrescribed by or in consultation with a cardiologist
    Resting heart rate
    Resting heart rate threshold>= 70 beats per minute
    ContextRequired with sinus rhythm and LVEF <=35% for ivabradine (Corlanor) eligibility
    Stability requirementMember clinically stable for at least 4 weeks on optimized regimen
    GFR exclusion threshold
    GFR exclusionGFR < 40 mL/min/1.73 m2 is an exclusion for deferasirox
    Related platelet exclusionPlatelet count <50,000/mcL excludes NTDT/CIO-BT use of deferasirox
    Continuation requirementContinuation requires decreased serum ferritin or LIC compared with baseline
    Serum ferritin (CIO-BT)
    CIO-BT ferritinSerum ferritin > 1000 mcg/L (consistent: at least two values within prior 2 months)
    NTDT ferritinSerum ferritin > 300 mcg/L (consistent: at least two values within prior 2 months)
    ContinuationContinuation interval typically 6 months with evidence of decreased ferritin or LIC
    Serum ferritin (NTDT)
    NTDT ferritin thresholdSerum ferritin > 300 mcg/L (consistent: at least two values within prior 2 months)
    LIC requirementNTDT may require liver iron concentration (LIC) >=5 mg Fe/g dw for initial therapy
    ContinuationContinuation requires decreased ferritin or reduction in LIC
    Eosinophils per HPF for EoE
    EoE eosinophil threshold>= 15 intraepithelial eosinophils per high power field (HPF)
    Additional requirementsSymptoms of esophageal dysfunction and exclusion of other causes; member weight >=15 kg
    Prior therapyInadequate response or intolerance to an 8‑week trial of specified therapies (PPI or topical esophageal corticosteroids)
    Eosinophil count for asthma/ COPD / EoE
    Asthma eosinophil thresholdsAsthma: >=150 cells/mcL baseline if steroid-dependent OR >=300 cells/mcL within past 12 months
    COPD thresholdCOPD: >=300 cells/mcL at baseline (Type 2 inflammation)
    EoE referenceEoE: >=15 intraepithelial eosinophils/HPF (see EoE criteria)
    Migraine frequency
    Episodic migraine4 to 14 headache days per month
    Chronic migraine>= 15 headache days per month
    DocumentationHeadache frequency must be documented and prior prophylactic trials recorded
    Height SDS for ISS
    ISS height SDSHeight SDS <= -2.25
    Midparental vs populationHeight >2.0 SD below midparental height OR >2.25 SD below population mean
    PrescriberPrescribed by or in consultation with an endocrinologist; bone age and provocative testing documented
    Height deviation thresholds
    Midparental/population deviationHeight >2.0 SD below midparental height OR >2.25 SD below population mean
    Growth velocityGrowth velocity >2 SD below mean is diagnostic criterion for GH deficiency
    Supporting testsBone age documentation and provocative testing required when applicable
    PIGF-1D height and IGF-1 thresholds
    Height SDS (PIGF-1D)Height SDS <= -3.0
    Basal IGF-1 SDSBasal IGF-1 SDS <= -3.0
    Growth hormone levelNormal or elevated growth hormone required by definition
    Opioid tolerance example
    Opioid tolerance exampleAt least one week with total daily dose >=30 mg oxycodone OR 60 mg oral morphine OR 8 mg oral hydromorphone OR 25 mg oral oxymorphone
    Pre-initiation evaluationMember must have been evaluated for non-opioid prescription pharmacologic treatment prior to high-dose opioid initiation
    Coverage contextApplies to new high-dose opioid therapy initial criteria; coverage remainder of contract year
    TOBI PODHALER FEV1 range
    TOBI PODHALER FEV1 rangeFEV1 between 25% and 80% predicted
    CAYSTON FEV1 comparatorCAYSTON requires FEV1 25%–75% predicted
    Prescriber requirementPrescribed by or in consultation with pulmonologist, infectious disease specialist or CF center specialist
    Nucala eosinophil thresholds
    Nucala initiation eosinophils>=150 cells/µL at initiation OR >=300 cells/µL within the past 12 months
    Clinical contextPlus exacerbation history or hospitalization and use with high-dose ICS + controller as specified
    PrescriberPrescribed by pulmonologist or allergy/immunology; reauth requires positive clinical response
    HES eosinophil threshold
    HES eosinophil threshold>=1000 cells/µL pre-treatment
    Other requirementsDiagnosis >=6 months and secondary causes ruled out; FIP1L1-PDGFRA negative; inadequate response/intolerance to corticosteroids or cytotoxic therapy
    AgeHES initial: member >=12 years
    CMV weight threshold
    CMV weight requirement>=35 kg
    Prior antiviral requirementInadequate response or intolerance to >=2 weeks of IV ganciclovir, oral valganciclovir, IV foscarnet, or IV cidofovir
    PrescriberPrescribed by transplant/infectious disease/oncology specialist
    Nexletol LDL-C thresholds
    Nexletol LDL-C (ASCVD) threshold>=70 mg/dL after statin (with ASCVD)
    Nexletol LDL-C (no ASCVD)>=100 mg/dL without ASCVD (documented within 120 days)
    Statin/ezetimibe requirementRequires prior statin therapy (or documented statin intolerance) and often >=8 weeks of ezetimibe when indicated
    Mean pulmonary artery pressure (dup)
    Mean pulmonary artery pressure (rest)>= 25 mm Hg at rest
    Mean pulmonary artery pressure (exertion)>30 mm Hg with exertion
    Diagnostic confirmationRequires right-heart catheterization or echocardiography
    LDL-C threshold for PCSK9 agents (HLA/ASCVD)
    PCSK9 LDL-C threshold (HLA/ASCVD)>= 70 mg/dL after >=8-week trial of at least moderate-intensity statin
    DocumentationLDL-C measured after statin trial or evidence of statin intolerance with supporting labs/notes
    Coverage durationsInitial commonly 6 months; continuation 12 months
    Platelet threshold for ITP (PROMACTA)
    ITP platelet threshold (PROMACTA)Baseline platelet count < 30,000/mcL
    Prior therapy requirementInadequate response or intolerance to corticosteroids, immunoglobulins, or splenectomy required prior to use
    PrescriberPrescribed by or in consultation with hematologist/oncologist
    BMD T-score for osteoporosis
    Osteoporosis BMD T-scoreBMD T-score <= -2.5
    Alternate criteriaHistory of osteoporotic fracture or multiple risk factors may substitute
    Prior therapy requirementInadequate response or intolerance to at least one other osteoporosis medicine may be required
    LDL-C threshold
    LDL-C thresholdLDL-C >= 70 mg/dL after >=8-week trial of at least moderate-intensity statin
    Statin intolerance definitionDocumented rhabdomyolysis or CK >10x ULN, or hepatotoxicity AST/ALT >3x ULN, or intolerable symptoms despite trials of two statins
    Coverage durationsInitial: 6 months; continuation: 12 months
    Untreated LDL-C for HoFH
    Untreated HoFH LDL-CUntreated LDL-C > 400 mg/dL
    Concomitant therapyMember must be receiving other lipid‑lowering therapy (e.g., statin, ezetimibe); not used with lomitapide
    Initial durationInitial authorization commonly 6 months; reauth requires positive clinical response
    Sirturo age/weight
    Minimum age/weight for SIRTUROMember >=5 years and weight >=15 kg
    Combination therapy requirementUse with >=3 other susceptible drugs (or >=4 likely‑susceptible if testing unavailable)
    AdministrationTo be administered by directly observed therapy (DOT)
    Sirturo coverage duration
    Coverage duration24 weeks
    Indication contextFor pulmonary MDR‑TB when used per combination‑therapy requirements
    PrescriberPrescribed by or in consultation with infectious disease specialist or pulmonologist
    Testosterone threshold
    Testosterone diagnostic thresholdTotal testosterone < 300 ng/dL measured on two separate early morning occasions
    Additional requirementsNormal prolactin and physical or cognitive symptoms of testosterone deficiency; prostate/breast cancer assessment
    Age considerationsSome formulations approved from age 12 (generic cypionate) but most products >=18 years
    Mean pulmonary artery pressure (dup)
    Mean pulmonary artery pressure (rest)>= 25 mm Hg at rest
    Mean pulmonary artery pressure (exertion)>30 mm Hg with exertion
    Required confirmationDiagnosis confirmed by right‑heart catheterization or echocardiography
    Xolair baseline total IgE
    Xolair baseline total IgE range>= 30 IU/mL and <= 1850 IU/mL
    Dosing guidanceDosing based on pretreatment total IgE level and body weight
    ReauthorizationReauth requires documentation of positive clinical response; initial/reauth durations commonly 12 months
    Baseline total serum IgE
    Baseline total serum IgE>= 30 IU/mL and <= 1850 IU/mL
    Indication contextApplies to IgE‑mediated food allergy and other Xolair indications per policy
    DocumentationMust document diagnosis/history of severe allergic responses and use with allergen avoidance

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior authorization required for listed drugs

    Many products listed in this document require prior authorization; see individual product entries for indication‑specific PA criteria including required prior trials, prescriber specialty, age limits, exclusions and coverage durations.

    Prior Authorization

    Armodafinil (MAC) PA

    Prior authorization is required for armodafinil when used for MAC lung disease and must document diagnosis, use as part of a combination antibacterial regimen, failure to achieve at least two negative sputum cultures after a minimum of 6 consecutive months of multidrug background therapy, age ≥18, and that the drug is prescribed by or in consultation with a pulmonologist or infectious disease specialist.

    • Diagnosis of MAC lung disease
    • Used as part of combination antibacterial regimen
    • Persistent positive cultures after ≥6 months of background therapy (no ≥2 negative sputum cultures)
    • Member ≥18 years
    • Prescribed by/consult pulmonologist or infectious disease specialist
    Prior Authorization

    CAYSTON PA

    Prior authorization is required for CAYSTON (aztreonam) for cystic fibrosis; the request must document CF diagnosis, evidence of Pseudomonas aeruginosa in the lungs, susceptibility to aztreonam, FEV1 between 25% and 75% predicted, member age ≥7, and that the prescriber is a pulmonologist, infectious disease specialist, or CF care center specialist.

    • CF diagnosis with Pseudomonas aeruginosa documented
    • Susceptibility showing organism sensitive to aztreonam
    • FEV1 25%–75% predicted
    • Member ≥7 years
    • Prescribed by/consult pulmonologist, ID specialist, or CF center specialist
    Prior Authorization

    DOPTELET PA

    DOPTELET prior authorization must document indication (CLD procedural support or chronic ITP), baseline platelet thresholds (CLD <50,000/mcL; ITP <30,000/mcL), required prior therapies for ITP, prescriber specialty (hematologist/oncologist), and Part B prerequisite where applicable.

    • CLD: baseline platelets <50,000/mcL and scheduled procedure (coverage 1 month)
    • ITP: baseline platelets <30,000/mcL plus inadequate response/intolerance to corticosteroids, IVIG, splenectomy, or rituximab (coverage 12 months)
    • Prescribed by or in consultation with hematologist/oncologist
    • Part B prerequisite: Yes for some uses
    Prior Authorization

    Prior authorization required (Dupixent examples)

    Prior authorization is required for Dupixent products by indication and must include documentation of diagnosis‑specific criteria, prior therapy failures or intolerances, and appropriate specialist prescriber or consultation.

    • Atopic dermatitis: inadequate response/intolerance to topical therapies
    • Asthma: eosinophil thresholds and exacerbation history plus controller therapy
    • EoE: ≥15 eosinophils/HPF, symptoms of esophageal dysfunction, weight and prior trial documentation
    • Prescriber specialty requirements per indication
    Prior Authorization

    EMGALITY prior authorization

    Emgality (including 300 mg dose) requires prior authorization documenting migraine diagnosis, headache frequency thresholds (episodic 4–14 days/month or chronic ≥15 days/month), and failure or intolerance to two listed prophylactic oral agents.

    • Episodic migraine: 4–14 headache days/month and failure/intolerance to two prophylactics
    • Chronic migraine: ≥15 headache days/month and failure/intolerance to two prophylactics
    • Prescribed by neurologist/headache specialist or certified pain specialist
    • Initial coverage typically 6 months
    Prior Authorization

    Growth hormone prior authorization

    Growth hormone products require prior authorization with documentation meeting indication‑specific diagnostic thresholds (height SDS, growth velocity, bone age, provocative testing), prescriber restriction to an endocrinologist (or consult), and typical approvals of 12 months with annual re‑evaluation for continuation.

    • Diagnostic documentation (height SDS, growth velocity, bone age, provocative testing)
    • Prescribed by or in consultation with an endocrinologist
    • Initial/continuation approvals commonly 12 months; annual re‑evaluation required
    Prior Authorization

    High-dose opioid prior authorization

    High‑dose opioid therapy (initial and continuation) requires prior authorization; initial high‑dose starts require opioid tolerance and prior evaluation of non‑opioid therapies, and continuation requires recent pain assessment, clinical benefit outweighing safety risks, and that the member is not in substance‑abuse treatment.

    • Initial: cancer pain OR chronic non‑cancer pain with opioid tolerance (example dosing thresholds provided) and prior evaluation for non‑opioid pharmacologic treatment
    • Continuation: pain assessment within 6 months, clinically meaningful improvement, and no active substance‑abuse treatment
    • Coverage duration: remainder of contract year (initial), continuation criteria reference morphine equivalent ≥90 mg/day
    Prior Authorization

    CMV — Prior authorization requirements

    CMV (Livtencity) prior authorization requires documentation of CMV infection/disease in a transplant recipient, inadequate response or intolerance to at least 2 weeks of listed antivirals (ganciclovir, valganciclovir, foscarnet, cidofovir), member weight ≥35 kg, and specialist prescriber (transplant/ID/oncology).

    • Diagnosis of CMV infection/disease
    • Recipient of HSCT or solid organ transplant
    • Inadequate response/intolerance to ≥2 weeks of listed antivirals
    • Member weight ≥35 kg
    • Prescribed by transplant/ID/oncology specialist; coverage duration 8 weeks
    Prior Authorization

    Nucala — Prior authorization requirements

    Nucala (mepolizumab) prior authorization requires documentation of indication‑specific eosinophil thresholds (e.g., ≥150 cells/µL at initiation or ≥300 cells/µL within 12 months), exacerbation history or hospitalization, concurrent high‑dose ICS plus controller therapy, and appropriate specialist prescriber involvement.

    • Blood eosinophils ≥150 cells/µL at initiation or ≥300 cells/µL within past 12 months
    • Exacerbation history (e.g., ≥2 exacerbations requiring systemic steroids or hospitalization) as specified per indication
    • Current treatment with high‑dose ICS plus another controller
    • Prescribed by pulmonologist or allergy/immunology specialist; initial/reauth coverage details apply
    Prior Authorization

    Nurtec — Prior authorization requirements

    Nurtec (rimegepant) prior authorization requires documentation of the indication: for acute use, episodic migraine diagnosis with <15 headache days/month and failure of a generic triptan; for preventive use, episodic migraine days and failure of a 4‑week trial of two listed prophylactic agents.

    • Acute: migraine diagnosis, <15 headache days/month, failure/intolerance to one generic triptan
    • Preventive: episodic migraine (4–18 migraine days/month) and failure/intolerance to two prophylactic agents after 4‑week trials
    • Prescriber: neurologist/headache specialist or certified pain specialist; initial 6 months, reauth 12 months
    Prior Authorization

    General PA evidence requirements

    Approve prior authorization requests when any one of the general evidence standards is met: FDA‑approved indication/regimen requested; NCCN Category 1 or 2A; supportive AHFS‑DI or Clinical Pharmacology narrative; Micromedex Class I/IIa/IIb recommendation; Lexi‑Drugs off‑label evidence level A; or supportive peer‑reviewed literature.

    • FDA‑approved indication/regimen
    • NCCN Drugs & Biologics Compendium Category 1 or 2A
    • Supportive compendia (AHFS, Clinical Pharmacology) or Micromedex Class I/IIa/IIb
    • Lexi‑Drugs off‑label evidence level A or peer‑reviewed literature
    Prior Authorization

    DMARD prior authorization

    DMARD/class biologic prior authorizations require documentation of diagnosis and inadequate response or intolerance to specified conventional DMARDs or prior therapies, with prescriber specialty restrictions applied for many indications.

    • Document diagnosis per indication
    • Document failure/intolerance to required conventional DMARD(s) or prior biologics per product
    • Prescriber: rheumatologist or specialty per indication
    Prior Authorization

    CF genotype confirmation

    For CFTR modulators and other CF therapies, prior authorization requires genotype confirmation when relevant (e.g., homozygous F508del for ORKAMBI) via an FDA‑cleared test if genotype is unknown, and prescriber should be a pulmonologist or CF care specialist.

    • Genotype confirmation (homozygous F508del) via FDA‑cleared test if unknown
    • Prescribed by or in consultation with pulmonologist or CF center specialist
    • Coverage indefinite where indicated
    Prior Authorization

    PROMACTA PA

    PROMACTA (eltrombopag) prior authorization requires diagnosis‑specific documentation (e.g., ITP with baseline platelets <30,000/mcL) and documentation of prior therapies; prescriber specialty is typically hematology/oncology.

    • ITP: baseline platelet count <30,000/mcL
    • Document prior inadequate response or intolerance to corticosteroids, IVIG, splenectomy, or rituximab
    • Prescribed by or in consultation with hematologist/oncologist; coverage durations vary
    Prior Authorization

    Hyperlipidemia / ASCVD prior authorization

    Prior authorization for lipid‑lowering agents (e.g., PCSK9, Nexletol/Nexlizet scenarios) requires documentation of diagnosis and LDL‑C thresholds: LDL‑C ≥70 mg/dL after ≥8 weeks of at least moderate‑intensity statin (or documented statin intolerance) or other specified LDL thresholds depending on indication.

    • LDL‑C ≥70 mg/dL after ≥8‑week trial of at least moderate‑intensity statin therapy OR documented statin intolerance
    • Nexletol/Nexlizet: often require prior statin and ≥8 weeks of ezetimibe adjunct unless intolerant
    • Initial durations commonly 6 months; continuation 12 months
    Prior Authorization

    RINVOQ / RINVOQ LQ prior authorization

    RINVOQ and RINVOQ LQ prior authorization requires documented diagnosis and prior inadequate response or intolerance to recommended DMARDs and/or TNF inhibitors as specified for each indication; prescriber specialty requirements apply.

    • Document diagnosis per indication (RA, PsA, AD, IBD, etc.)
    • Document failure/intolerance to required prior DMARDs and/or TNF inhibitors
    • Prescribed by or in consultation with rheumatologist or specialty per indication
    Prior Authorization

    VYNDAQEL prior authorization

    VYNDAQEL prior authorization requires diagnostic confirmation of ATTR‑CM (TTR mutation, biopsy, or supportive imaging with exclusion of light‑chain amyloidosis), documentation of heart failure history and NYHA class I–III, and cardiology prescriber involvement.

    • Confirm ATTR‑CM by TTR mutation, biopsy, or imaging/scintigraphy with exclusion of light‑chain amyloidosis
    • Document HF history and NYHA Functional Class I–III
    • Prescribed by or in consultation with a cardiologist; initial/reauth 12 months
    Prior Authorization

    Bosentan (PAH) prior authorization requirement

    Bosentan (Tracleer) prior authorization for PAH initial therapy requires WHO Group I PAH with NYHA Class II–IV, hemodynamic confirmation by catheterization or echocardiography including mean PAP ≥25 mm Hg at rest (or >30 mm Hg with exertion), and prescriber cardiologist or pulmonologist.

    • PAH WHO Group I with NYHA FC II–IV
    • Diagnostic confirmation by right‑heart catheterization or echocardiography
    • Mean pulmonary artery pressure ≥25 mm Hg at rest (or >30 mm Hg with exertion)
    • Prescribed by/consult cardiologist or pulmonologist; initial 6 months
    Prior Authorization

    Tremfya prior authorization requirement

    Tremfya prior authorization requires indication‑specific prior trials: for PsO and PsA inadequate response or intolerance to two specified agents (lists vary), and for UC/CD trials as specified or use as maintenance after IV induction; concurrent biologic therapy is an exclusion.

    • Plaque psoriasis/PsA: inadequate response or intolerance to two listed agents (e.g., Cosentyx, Enbrel, Humira, Skyrizi, Ustekinumab, Otezla)
    • UC/CD: inadequate response/intolerance to listed agents or used as maintenance after IV induction
    • Exclusion: concurrent biologic DMARDs or TNF antagonists; prescriber specialist required
    Prior Authorization

    Tymlos prior authorization requirement

    Tymlos prior authorization for postmenopausal osteoporosis requires documentation of PMO with high fracture risk (multiple vertebral fractures, BMD T‑score ≤ −2.5, or prior osteoporotic fracture) and inadequate response or intolerance to one listed therapy; cumulative lifetime limits apply.

    • Diagnosis of PMO with high fracture risk (multiple vertebral fractures, BMD T‑score ≤ −2.5, or osteoporotic fracture)
    • Inadequate response/intolerance to one listed therapy (e.g., bisphosphonates, HRT, SERMs, denosumab)
    • Coverage typically remainder of contract year; cumulative lifetime therapy limits noted
    Prior Authorization

    Vowst prior authorization requirement

    Vowst prior authorization for prevention of recurrent C. difficile infection requires documentation of recurrent CDI (≥2 recurrences in 12 months), positive stool toxin test, completion of at least 10 days of specified antibiotics 2–4 days prior, completion of recommended bowel prep, and prescriber specialty (gastroenterology or infectious disease).

    • ≥2 recurrent CDI episodes within 12 months and positive stool test for C. difficile toxin
    • Completed ≥10 consecutive days of oral vancomycin or fidaxomicin 2–4 days prior
    • Completed recommended bowel prep the day before and ≥8 hours prior to initiation
    • Prescribed by/consult gastroenterologist or ID specialist; coverage 14 days
    Prior Authorization

    Xolair (OMALIZUMAB) prior authorization

    Xolair (omalizumab) prior authorization for IgE‑mediated food allergy requires documentation of diagnosis or severe allergic history, baseline total serum IgE between 30–1850 IU/mL, and dosing per IgE and body weight; initial and reauthorization durations are 12 months.

    • Diagnosis or clinical history of IgE‑mediated food allergy or history of severe allergic response/anaphylaxis
    • Baseline total IgE ≥30 and ≤1850 IU/mL
    • Dosing based on pretreatment IgE and body weight
    • Prescribed by appropriate specialist; initial/reauth 12 months
    Prior Authorization

    XYREM prior authorization

    XYREM prior authorization requires diagnosis confirmation by polysomnography or MSLT for cataplexy or EDSN (or prescriber justification if sleep study not feasible), prescriber specialty (neurologist, psychiatrist, or sleep specialist), and prior therapy failure for EDSN; coverage duration is 12 months.

    • Diagnosis confirmed by PSG or MSLT or prescriber justification if not feasible
    • EDSN: prior inadequate response or intolerance to modafinil/armodafinil
    • Prescribed by neurologist, psychiatrist, or sleep specialist; reauth annually with efficacy documentation
    • Exclusion: concurrent sedative hypnotics and alcohol
    Prior Authorization

    ZTALMY and ZURZUVAE prior authorization

    ZTALMY prior authorization requires genetic confirmation of CDKL5 mutation, documentation of motor seizures, and trial/failure or intolerance to two formulary anticonvulsants with neurologist prescriber; ZURZUVAE requires failure/intolerance to one generic SSRI and one generic SNRI and is limited to 14 days.

    • ZTALMY: CDKL5 mutation documented, motor seizures present, failure/intolerance to two formulary anticonvulsants, neurologist prescriber, member ≥2 years, coverage indefinite
    • ZURZUVAE: PPD diagnosis, failure/intolerance to one generic SSRI and one generic SNRI, coverage limited to 14 days
    Note

    Index: prior authorization location references

    The index section lists drug names and points to product‑specific policy pages; it does not itself include prior authorization rules—providers must consult the referenced policy pages for PA criteria.

    Step Therapy

    Step therapy referenced

    Step therapy is used for some drugs; detailed step therapy rules are contained in the separate 2025 Utilization Management Criteria: Step Therapy document—refer to that document and product entries for specific step requirements.

    Step Therapy

    LYBALVI step requirement

    LYBALVI new starts require documented trial of two generic formulary antipsychotics prior to approval.

    • Trial of two generic formulary antipsychotics for new starts
    Step Therapy

    Antipsychotic step trials

    For certain antipsychotic indications the policy requires trials of two atypical antipsychotics (e.g., aripiprazole, quetiapine, risperidone, olanzapine) as prior step therapy before authorizing listed agents.

    • Inadequate response or intolerance to TWO atypical antipsychotics prior to approval
    Step Therapy

    Migraine prophylaxis step requirement (Emgality)

    Emgality for migraine prophylaxis requires failure or intolerance to two listed oral prophylactic agents before approval; headache frequency must be documented per episodic or chronic thresholds.

    • Failure/intolerance to two listed oral prophylactic medications
    • Document episodic (4–14 days/month) or chronic (≥15 days/month) headache frequency
    Step Therapy

    Biologic/rheumatologic step therapy

    Certain biologic and rheumatologic agents require inadequate response or intolerance to specified prior therapies (e.g., methotrexate for RA) before approval; prescriber specialty and concurrent biologic exclusions apply per product.

    • Document failure/intolerance to specified conventional therapies (e.g., methotrexate)
    • Trials of specified biologics/targeted agents as listed per indication
    • Prescriber specialty (rheumatologist, dermatologist, gastroenterologist) required
    Step Therapy

    Nexletol/Nexlizet — Step therapy

    Nexletol/Nexlizet prior authorization requires prior statin therapy (unless statin intolerant) and in many scenarios at least 8 weeks of ezetimibe as an adjunct before approval.

    • LDL‑C documented and prior ≥8‑week trial of statin therapy at maximally tolerated dose or documented statin intolerance
    • ≥8 weeks of ezetimibe as adjunct required in many scenarios unless contraindicated/intolerant
    Step Therapy

    GLP-1 agents — Step therapy

    For specified GLP‑1 agents, step therapy requires inadequate response or intolerance to two preferred brand GLP‑1 agents (e.g., Ozempic, Trulicity, Rybelsus, Mounjaro, Victoza) with documentation (commonly 90 days each) prior to approval.

    • Medical records confirming T2DM diagnosis (A1C/FPG/OGTT) where applicable
    • Inadequate response/intolerance to two preferred GLP‑1 brand agents with ~90‑day trials each
    Step Therapy

    Step requirements for branded vs generic

    Some products require trial and inadequate response to lower‑cost or generic alternatives before brand approval; documentation of failure or intolerance to the alternative is required.

    • Trial and inadequate response/intolerance to generic or lower‑cost alternative (example: generic tadalafil before brand PAH product)
    Step Therapy

    Step therapy for biologics

    Many biologic therapies require trials of indicated alternative biologics or targeted therapies (e.g., TNF inhibitors, Cosentyx, Adalimumab) with documentation of inadequate response or intolerance prior to approval.

    • Document failure/intolerance to the specified alternative biologics/targeted therapies per indication
    • Concurrent biologic therapy is an exclusion across many entries
    Step Therapy

    Tremfya step therapy

    Tremfya requires prior inadequate response or intolerance to two listed agents (e.g., Cosentyx, Enbrel, Humira, Skyrizi, Ustekinumab, Otezla) before approval for plaque psoriasis and related indications.

    • Document failure/intolerance to two listed prior agents
    • Exclusion for concurrent biologic DMARDs
    Step Therapy

    Xifaxan step therapy for IBS-D

    Rifaximin (Xifaxan) for IBS‑D requires inadequate response or intolerance to a TCA or SSRI plus dicyclomine (both components) prior to approval and is limited to a maximum of three total courses (42 days) across therapy.

    • Failure/intolerance to ONE TCA or ONE SSRI AND dicyclomine
    • Member must not exceed three total courses (42 days total)
    Step Therapy

    Uptravi step therapy

    Uptravi for PAH initial therapy requires inadequate response or intolerance to two of: an endothelin receptor antagonist, a phosphodiesterase inhibitor, or riociguat, as part of step therapy prior to approval.

    • Document failure/intolerance to two of the listed drug classes prior to Uptravi
    • Prescribed by/consult cardiologist or pulmonologist
    Step Therapy

    Step therapy / prior trials (examples)

    Several products require documentation of prior trial(s) and reasons for failure or intolerance before approval (e.g., XYREM requires prior modafinil/armodafinil for EDSN; ZTALMY requires two formulary anticonvulsants), per product‑specific step therapy rules.

    • Document prior trial(s) and reason for failure/intolerance
    • Follow product‑specific step trial requirements as listed
    Note
    Documentation Required

    XTAMPZA ER required documentation

    Providers must obtain and retain documentation specific to each PA: for XTAMPZA ER either prior use of two generic opioids or documentation of both a history/potential for drug abuse and a current patient‑prescriber opioid treatment agreement.

    • Either prior use of TWO generic opioids OR both: (a) history or potential for drug abuse in individual/household AND (b) current patient‑prescriber opioid treatment agreement
    Documentation Required

    Acthar required documentation

    Acthar (H.P. Acthar Gel) PA documentation must include indication‑specific evidence (e.g., dosing per FDA for infantile spasms, diagnosis confirmation, prior trials of systemic steroids or DMARDs as applicable, and relevant lab thresholds such as proteinuria >3.5 g/24h for nephrotic syndrome).

    • Infantile spasms: dosing per FDA labeling (≤150 U/m2 daily) and neurologist/neonatologist prescriber
    • Nephrotic syndrome: proteinuria >3.5 g/24h and serum albumin <3 mg/dL where applicable
    • Prior inadequate response/intolerance to required systemic therapies per indication
    Documentation Required

    MAC lung disease documentation

    For MAC lung disease (Arikayce/Armodafinil context), documentation must include diagnosis of MAC lung disease, that the medication is part of a combination antibacterial regimen, and evidence that the patient has not achieved at least two negative sputum cultures after a minimum of 6 consecutive months of multidrug background therapy.

    • Diagnosis of MAC lung disease
    • Use as part of a combination antibacterial regimen
    • Persistent positive sputum cultures after ≥6 months of background therapy (no ≥2 negative cultures)
    Documentation Required

    EoE documentation

    EoE documentation for Dupixent and related agents must include diagnosis with symptoms of esophageal dysfunction, biopsy showing at least 15 intraepithelial eosinophils per high‑power field, exclusion of other causes, member weight ≥15 kg, and prior inadequate response or intolerance to an 8‑week trial of specified therapies.

    • Symptoms of esophageal dysfunction (dysphagia, food impaction, etc.)
    • ≥15 intraepithelial eosinophils per HPF on biopsy
    • Exclusion of other causes and member weight ≥15 kg
    • Prior inadequate response/intolerance to an 8‑week trial of PPI or topical esophageal corticosteroids
    Documentation Required

    Baseline platelet count and prior therapies for CLD/ITP

    For DOPTELET uses in CLD/ITP, providers must document baseline platelet counts meeting the thresholds for the requested indication and prior therapies/intolerances (e.g., corticosteroids, IVIG, splenectomy, rituximab) for ITP.

    • CLD procedure support: baseline platelets <50,000/mcL and scheduled procedure
    • ITP initial: baseline platelets <30,000/mcL and failure/intolerance to listed prior therapies
    • Prescriber: hematologist/oncologist
    Documentation Required

    Diagnosis documentation and prior trials for atopic dermatitis, asthma, CRSwNP, EoE, bullous pemphigoid

    For atopic dermatitis, asthma, CRSwNP, EoE and bullous pemphigoid, prior authorization documentation must include objective diagnostic measures and prior trials as specified (e.g., eosinophil counts, biopsy for BP, weight and biopsy/histology for EoE); specialist prescriber or consultation is required.

    • AD: inadequate response to topical therapies; prescriber dermatologist/allergist/immunologist
    • Asthma: eosinophil thresholds and exacerbation history; prescriber pulmonologist/allergist
    • CRSwNP: diagnosis plus intranasal corticosteroid use; prescriber ENT/allergist
    • BP: biopsy confirmation; prescriber dermatologist
    Documentation Required

    Headache frequency documentation and prophylactic trial requirements

    For migraine PA (e.g., Emgality, Nurtec), providers must document headache frequency consistent with episodic (4–14 days/month) or chronic (≥15 days/month) definitions and trials of required prophylactic medications (two agents) or contraindications.

    • Document episodic vs chronic headache day frequency per thresholds
    • Document failure or intolerance to two prophylactic medications (4‑week trials) or contraindications
    • Prescriber: neurologist or headache specialist
    Documentation Required

    Epidiolex baseline testing documentation

    Epidiolex initiation requires baseline CBC, liver transaminases and total bilirubin prior to starting therapy for Dravet, LGS, or TSC indications and specialist (neurologist) prescriber involvement.

    • Baseline CBC, AST/ALT and total bilirubin prior to initiation
    • Prescribed by or in consultation with a neurologist
    • Concurrent use with additional antiepileptics as specified
    Documentation Required

    Growth failure required documentation

    Growth failure documentation must include height measurements relative to midparental height or population mean, growth velocity, bone age, and results of provocative GH testing when applicable; prescriber is an endocrinologist and approvals are commonly 12 months.

    • Height SDS and deviation thresholds, growth velocity data, bone age documentation
    • Abnormal provocative testing results where applicable
    • Prescribed by/consult endocrinologist; initial/continuation typically 12 months
    Documentation Required

    Kalydeco mutation documentation

    Kalydeco (ivacaftor) requests require documentation of a CFTR mutation responsive to ivacaftor by an FDA‑cleared mutation test, with verification by bi‑directional sequencing when recommended.

    • Document CFTR mutation responsive to ivacaftor via FDA‑cleared test
    • Bi‑directional sequencing verification when recommended
    • Prescribed by/consult pulmonologist or CF center specialist
    Documentation Required

    DM2 documentation for GLP-1 agents

    For GLP‑1 and related agents for type 2 diabetes, medical records must confirm diagnosis (e.g., A1C ≥6.5% or FPG ≥126 mg/dL or 2‑hr OGTT ≥200 mg/dL) and document inadequate response or intolerance to a minimum 90‑day supply of two preferred brand GLP‑1 agents.

    • Confirm diagnosis of type 2 diabetes via labs or chart documentation
    • Document failure/intolerance to two preferred brand GLP‑1 agents (≥90 days each)
    Documentation Required

    Posaconazole documentation

    Posaconazole prior authorization must include documentation of the invasive aspergillosis or Candida diagnosis and prior inadequate response or intolerance to voriconazole when seeking prophylaxis; prescriber should be an infectious disease, transplant, hematology/oncology specialist, or part of chemo prophylaxis.

    • Diagnosis of invasive aspergillosis or need for prophylaxis
    • Prior inadequate response/intolerance to voriconazole when prophylaxis sought
    • Prescribed by infectious disease/transplant/oncology specialist or as part of chemo protocol
    Documentation Required

    Nuplazid documentation

    Nuplazid prior authorization requires documentation of inadequate response or intolerance to quetiapine or clozapine for Parkinson disease psychosis prior to approval.

    • Document failure/intolerance to quetiapine or clozapine
    • Prescriber neurologist or psychiatrist per product guidance
    Documentation Required

    PAH required documentation

    PAH medication requests must include diagnostic confirmation (WHO Group I PAH), NYHA functional class, and hemodynamic confirmation (right‑heart catheterization or echocardiography) including mean pulmonary artery pressure meeting policy thresholds.

    • Diagnosis of PAH WHO Group I with NYHA FC II–IV
    • Diagnostic confirmation by catheterization or echocardiography
    • Document mean PAP ≥25 mm Hg at rest (or >30 mm Hg with exertion)
    Documentation Required

    Lipid therapy documentation

    For lipid‑lowering agents (PCSK9 and similar), documentation must include LDL‑C values measured after an ≥8‑week trial of at least moderate‑intensity statin therapy or evidence of statin intolerance with supporting labs or clinical notes.

    • LDL‑C ≥70 mg/dL after ≥8 weeks of moderate‑intensity statin (or documented statin intolerance)
    • Supporting documentation of statin intolerance (CK, AST/ALT, clinical notes)
    Documentation Required

    Diagnostic confirmation and response documentation (ATTR-CM, BVAS)

    For diagnoses requiring diagnostic confirmation (e.g., ATTR‑CM, ANCA‑vasculitis), PA and reauthorization must include the appropriate diagnostic test results (biopsy, imaging, genetic test) and evidence of positive clinical response for continuation when specified.

    • ATTR‑CM: TTR mutation, biopsy, or supportive imaging + scintigraphy and exclusion of light‑chain amyloidosis
    • TAVNEOS reauth: documentation of sustained remission assessed by BVAS
    • Reauthorization often requires evidence of positive clinical response
    Documentation Required

    Testosterone initial diagnostic documentation

    Initial testosterone therapy requires attestation that hypogonadism diagnosis was confirmed by two early‑morning total testosterone levels <300 ng/dL on separate occasions, a normal prolactin level, and appropriate symptoms, with prostate/breast cancer screening considerations documented.

    • Two early‑morning total testosterone measurements <300 ng/dL on separate occasions
    • Normal prolactin level and documentation of symptoms of testosterone deficiency
    • Document prostate/breast cancer history or risk–benefit assessment as required
    Documentation Required

    Vowst required documentation

    Vowst authorization requires documentation of ≥2 recurrent CDI episodes within 12 months, positive stool toxin test, completion of at least 10 days of specified antibiotics 2–4 days prior to initiation, and completion of recommended bowel prep prior to dosing.

    • ≥2 recurrent CDI episodes in 12 months with positive stool toxin test
    • Completed ≥10 days of oral vancomycin or fidaxomicin 2–4 days prior
    • Completed recommended bowel prep day before and ≥8 hours prior to initiation
    Documentation Required

    Xolair IgE and dosing documentation

    Xolair for IgE‑mediated food allergy requires baseline total IgE between 30–1850 IU/mL and dosing per IgE and weight; documentation must include diagnosis or clinical history and history of severe allergic response where applicable.

    • Baseline total serum IgE ≥30 and ≤1850 IU/mL
    • Dosing per pretreatment IgE and body weight
    • Document diagnosis/clinical history and history of severe allergic response/anaphylaxis
    Documentation Required

    Xolair required documentation (severe allergic history)

    Xolair authorization must include documentation of diagnosis or clinical history and history of severe allergic response (including anaphylaxis) when used for IgE‑mediated food allergy; dosing must follow IgE and weight guidance.

    • Clinical history or diagnosis supporting IgE‑mediated food allergy
    • History of severe allergic response/anaphylaxis where applicable
    • Dosing based on pretreatment IgE level and body weight
    Documentation Required

    XYREM required documentation

    XYREM documentation must confirm diagnosis by polysomnography (PSG) or MSLT for cataplexy or EDSN, or include prescriber justification if sleep study is not feasible; for EDSN, document prior inadequate response or intolerance to modafinil/armodafinil.

    • PSG or MSLT confirmation or prescriber justification if study not feasible
    • For EDSN: prior inadequate response/intolerance to modafinil or armodafinil
    • Prescriber specialty: neurologist, psychiatrist, or sleep specialist
    Documentation Required

    ZTALMY and ZURZUVAE required documentation

    ZTALMY authorization requires documentation of CDKL5 mutation, presence of motor seizures, and trial/failure or intolerance of two formulary anticonvulsants; ZURZUVAE requires documentation of failure/intolerance to one generic SSRI and one generic SNRI and is limited to 14 days.

    • ZTALMY: CDKL5 mutation documented, motor seizures specified, failure/intolerance to two anticonvulsants, neurologist prescriber
    • ZURZUVAE: PPD diagnosis and failure/intolerance to one SSRI and one SNRI; therapy limited to 14 days
    Note
    Denial Risk

    Prior authorization required — failure to obtain may result in non-coverage

    Failure to obtain required prior authorization may result in the plan not covering the drug.

    Denial Risk

    CAYSTON denial triggers

    CAYSTON may be denied if FEV1 is not between 25% and 75% predicted, if Pseudomonas aeruginosa is not demonstrated in the lungs, or if susceptibility to aztreonam is not documented.

    • FEV1 outside 25%–75% predicted
    • No evidence of Pseudomonas aeruginosa in lungs
    • No susceptibility showing P. aeruginosa sensitive to aztreonam
    Denial Risk

    CORLANOR denial triggers

    Corlanor (ivabradine) may be denied if left ventricular ejection fraction is >35%, resting heart rate <70 bpm, or if the patient is not clinically stable on an optimized regimen for at least 4 weeks as required.

    • LVEF >35%
    • Resting heart rate <70 bpm
    • Not clinically stable on optimized regimen for ≥4 weeks
    Denial Risk

    Deferasirox renal/platelet exclusion

    Deferasirox requests may be denied if the member's GFR is <40 mL/min/1.73m2 or platelet counts <50,000/mcL for NTDT or CIO‑BT indications per exclusion criteria.

    • GFR <40 mL/min/1.73 m2
    • Platelet count <50,000/mcL for NTDT/CIO‑BT
    Denial Risk

    Baseline platelet and other denial triggers for CLD/ITP

    Requests lacking required baseline platelet counts or prior therapy documentation for CLD procedural support or ITP (e.g., platelets not meeting <50,000/mcL for CLD or <30,000/mcL for ITP) may be denied.

    • Missing baseline platelet counts meeting thresholds
    • Lack of documented prior therapies or intolerances where required
    Denial Risk

    Migraine therapy denial triggers

    For migraine therapies, requests may be denied for insufficient documentation of required prophylactic medication trials or if documented headache frequency does not meet episodic or chronic thresholds required by the policy.

    • Insufficient documentation of two prophylactic medication trials
    • Headache frequency not documented as episodic (4–14 days/month) or chronic (≥15 days/month)
    Denial Risk

    Concurrent biologic therapy exclusion denial risk

    Concurrent therapy with another biologic (including other biologic DMARDs or injectable CGRP inhibitors) is an exclusion in many biologic and allergy/asthma entries and may trigger denial if documented.

    • Concurrent biologic therapy for same indication is excluded
    • Examples: concurrent biologics for asthma/allergic conditions, CGRP inhibitors
    Denial Risk

    Growth hormone documentation denial triggers

    Growth hormone requests lacking required diagnostic documentation (height/velocity measures, bone age, abnormal provocative testing) risk denial.

    • Missing height SDS or growth velocity documentation
    • No bone age or provocative testing results when applicable
    Denial Risk

    High-dose opioid prerequisites denial triggers

    High‑dose opioid therapy requests without documentation of opioid tolerance (per example thresholds) and prior evaluation of non‑opioid pharmacologic treatment may be denied.

    • No documentation of opioid tolerance (e.g., ≥1 week at specified opioid dosing thresholds)
    • No evidence of prior evaluation for non‑opioid pharmacologic treatment
    Denial Risk

    CMV — triggers for denial

    CMV requests may be denied if inadequate response or intolerance to listed prior antivirals is not documented, or if transplant recipient status or member weight ≥35 kg is not documented per PA requirements.

    • No documentation of transplant recipient status
    • No documentation of prior inadequate response/intolerance to required antivirals
    • Member weight <35 kg (when threshold not met)
    Denial Risk

    Nucala — concurrent biologic exclusion

    Nucala requests that document concurrent use of other biologics for asthma/allergic conditions will be excluded and may be denied.

    • Concurrent biologic therapy (e.g., benralizumab, dupilumab, omalizumab, reslizumab) is an exclusion
    Denial Risk

    Tavaborole diagnostic and prior therapy requirement

    Tavaborole will be denied if confirmatory diagnostic testing (KOH, culture, or histology) is missing or if there is no documentation of inadequate response/intolerance to both oral terbinafine and either oral itraconazole or topical ciclopirox.

    • Missing KOH, culture, or histology confirmation of dermatophyte
    • No documentation of failure/intolerance to oral terbinafine and either oral itraconazole or topical ciclopirox
    Denial Risk

    Evidence-based indication required — denial risk if unsupported

    Requests may be denied if the indication or regimen is not FDA‑approved and is not supported by recognized compendia or peer‑reviewed literature per the general PA evidence standards.

    • Indication/regimen not FDA‑approved and not supported by NCCN, AHFS/Clinical Pharmacology, Micromedex, Lexi, or peer‑reviewed literature
    Denial Risk

    PAH diagnostic confirmation required — denial risk

    For PAH medications, lack of diagnostic confirmation by right‑heart catheterization or echocardiography and absence of documented mean pulmonary artery pressure ≥25 mm Hg at rest (or >30 mm Hg with exertion) can trigger denial.

    • No right‑heart catheterization or echocardiography confirmation
    • Mean PAP not documented to meet ≥25 mm Hg at rest (or >30 mm Hg with exertion)
    Denial Risk

    Missing required prior therapy documentation — denial risk

    Requests lacking documentation of required diagnosis or failure/intolerance to specified prior therapies (e.g., statin trial for lipid agents, TNF inhibitor trials for rheumatologic agents) may be denied.

    • Missing documentation of required prior therapy trials
    • Missing diagnosis documentation as specified by product criteria
    Denial Risk

    Concurrent biologic therapy exclusion — denial risk

    Concurrent therapy with biological DMARDs or other TNF antagonists for indications such as PsO, PsA, UC, CD is an exclusion and will trigger denial.

    • Concurrent biologic DMARD or TNF antagonist therapy documented
    Denial Risk

    Course limit for Rifaximin (IBS-D) — denial risk

    For rifaximin in IBS‑D, requests exceeding three total courses (42 days total) will be denied per the policy course‑limit rule.

    • Exceeding three total courses (42 days total) of rifaximin for IBS‑D
    Denial Risk

    XYREM exclusion — denial risk

    Concurrent use of sedative hypnotics and alcohol is an exclusion for XYREM and may trigger denial.

    • Concurrent sedative hypnotic use and alcohol documented
    Note

    Index: section note — no auth rules present in index

    The index section does not contain authorization rules itself; it only lists drug names and points to the detailed policy pages where PA/step/documentation rules are defined. Providers must consult the referenced pages for actionable requirements.

    Initial Authorization Requirements

    Reauthorization / Continuing Therapy

    Step Therapy Rules and Required Trials

    Step therapy note
    Step therapy is referenced; detailed step criteria are maintained in the separate 2025 Utilization Management Criteria: Step Therapy document and the formulary flags drugs that require step therapy.
    DrugStep requirement
    LYBALVINew starts require a trial of two generic formulary antipsychotics prior to approval.
    ExamplesStep requirement
    CIMZIA (certolizumab) — examplesRequires inadequate response or intolerance to specified prior biologic/targeted agents (generally trials of two listed agents per indication) before approval.
    COSENTYX (secukinumab) — examplesRequires prior inadequate response or intolerance to indicated prior therapies (e.g., NSAIDs, methotrexate, other biologics) as listed per indication before approval.
    Clinical area / drugRequired prior trials
    Migraine prophylaxis (e.g., Emgality)Failure or intolerance to two listed oral prophylactic agents (4‑week trials) required before approval; documentation of headache frequency (episodic 4–14 days/month or chronic ≥15 days/month) also required.
    Biologic/advanced therapies for IBD (e.g., Entyvio maintenance)Inadequate response or intolerance to two specified agents (e.g., adalimumab, ustekinumab, upadacitinib, tofacitinib, risankizumab) or used as maintenance following IV induction; trials required prior to subcutaneous maintenance in many cases.
    ScopeStep therapy expectation
    Biologic and rheumatologic agents (multiple products)Require inadequate response or intolerance to specified prior therapies (examples include methotrexate, TNF inhibitors, other biologics) — typically trials of one or two agents depending on indication before approval.
    Drug(s)Prior therapy requirement
    Nexletol / Nexlizet (bempedoic acid ± ezetimibe)Require prior statin therapy (≥8 weeks at maximally tolerated dose) unless statin‑intolerant, and prior ezetimibe (typically ≥8–12 weeks of generic ezetimibe) as adjunct before approval; documented statin intolerance pathways also accepted.
    Class / agentsStep requirement details
    GLP‑1 / GLP‑1‑like agents (class example)Require inadequate response or intolerance to a minimum 90‑day supply of two preferred brand GLP‑1 agents (examples listed: Ozempic, Trulicity, Rybelsus, Mounjaro, Victoza) prior to approval.
    SituationStep requirement
    Brand vs generic alternativesSome branded products require trial and inadequate response or intolerance to lower‑cost/generic alternatives before brand approval (example: generic tadalafil required prior to some brand PAH coverage).
    General ruleAllowance for exceptions
    Trials of indicated prior therapiesTrials of required prior therapies (DMARDs, TNF inhibitors, other listed agents) are required before approval unless the prescriber documents that a trial is inappropriate or would be harmful.
    DrugSpecific step trial requirement
    Tremfya (guselkumab)Requires prior inadequate response or intolerance to two listed agents (examples include Cosentyx, Enbrel, Humira, Skyrizi, Ustekinumab, Otezla) before approval for plaque psoriasis and related indications.
    IndicationPrior therapies required before rifaximin (Xifaxan) approval for IBS‑D
    IBS‑D (irritable bowel syndrome with diarrhea)Require inadequate response or intolerance to BOTH: (A) one tricyclic antidepressant OR one SSRI AND (B) dicyclomine prior to approval; course limits (no more than three total courses/42 days) apply for repeat therapy.
    Documentation requiredPurpose
    Document prior trial(s) and reason for failure or intolerance (e.g., adverse effects, lack of efficacy, contraindication)Required to support approval when step therapy requires prior agent failure — prescriber must document trials, durations, and rationale for exceptions if applicable.

    Quantity and Duration Limits

    LIVTENCITY — quantity/limit placeholder
    Quantity/limit placeholderSee LIVTENCITY CMV criteria (quantity limits not specified in excerpt)
    Coverage durationInitial authorization duration typically 8 weeks for CMV use
    Prior authorizationPA required with transplant recipient status, prior antiviral failure, and weight >=35 kg

    Site of Care and Part B/Part D Notes

    Billing Rule

    Infusion center — Part B vs Part D considerations

    For infusion or physician‑administered products, note that benefit review may determine Part B vs Part D responsibility which can affect site‑of‑care billing and payment; consult the product entry and payer guidance.

    Note

    Infusion center — IV induction before SC maintenance (Entyvio example)

    Some medications (e.g., Entyvio) may require IV induction administration prior to approval of subcutaneous maintenance dosing; providers should document IV induction where applicable and coordinate site‑of‑care accordingly.

    • Document IV induction when required (Entyvio IV before SC maintenance)
    • Prescriber: gastroenterologist or specialist as indicated
    Note

    Infusion center — pulmonologist/ID/CF specialist prescribing

    Certain inhaled or specialized therapies for pulmonary infections should be prescribed by or in consultation with a pulmonologist, infectious disease specialist, or CF center specialist; site‑of‑care (infusion center/clinic) and specialist involvement are required for authorization.

    • Prescribed by/consult pulmonologist, infectious disease, or CF care center specialist
    • Site‑of‑care and specialist documentation required for PA
    Note

    Hospital outpatient — transplant/ID/oncology prescribing

    For transplant‑related antivirals and some oncology agents, prior authorization requires prescriber involvement from transplant, infectious disease, or oncology specialists and may point to hospital outpatient or infusion site for administration.

    • Prescribed by/consult transplant, infectious disease, or oncology specialist
    • Coverage durations and administration site may align with hospital outpatient or infusion center
    Note

    Infusion center | hospital outpatient | office — antifungal prophylaxis/site notes

    Some antifungal prophylaxis or treatment (e.g., posaconazole) requires specialist prescribing and may be delivered in infusion center, hospital outpatient, or office settings as part of chemotherapy prophylaxis protocols.

    • Prescribed by infectious disease/transplant/hematology‑oncology specialist or as part of chemo prophylaxis
    • Site‑of‑care may be infusion center, hospital outpatient, or office depending on regimen

    Policy Background

    This formulary section summarizes the clinical prerequisites the plan uses to approve drug coverage under the AmeriHealth Medicare PPO benefit. It highlights that approvals generally require documented diagnosis, prior trials or intolerance to specified agents, prescriber specialty where indicated, and objective measures or lab thresholds when applicable. The guidance is intended to ensure appropriate, evidence‑based use of specialty and high‑cost medications.

    Key Definitions and Diagnostic Criteria

    Utilization management definition
    DefinitionUtilization management: Plan-applied restrictions and limits on drug coverage including prior authorization, step therapy, and quantity limits
    Document useThis UM criteria document is used with the Formulary; if a drug is noted 'PA' see this document for restrictions
    ContactFor questions call AmeriHealth Medicare PPO Member Help Team (number in document)
    Eosinophilic esophagitis (EoE) definition
    DefinitionEosinophilic esophagitis (EoE): Symptoms of esophageal dysfunction plus >=15 intraepithelial eosinophils per HPF after exclusion of other causes
    Weight requirementMember weight >=15 kg required for therapy in criteria
    Prior therapyInadequate response or intolerance to an 8‑week trial of specified therapies (PPI or topical esophageal corticosteroids)
    Growth Hormone Deficiency (children)
    DefinitionGrowth Hormone Deficiency (children): Defined by height or growth velocity criteria and abnormal provocative testing with bone age documentation
    Diagnostic examplesHeight >2.0 SD below midparental height OR >2.25 SD below population mean; growth velocity >2 SD below mean
    PrescriberPrescribed by or in consultation with an endocrinologist
    Idiopathic Short Stature (ISS)
    DefinitionIdiopathic Short Stature (ISS): Height SDS <= -2.25
    DocumentationSupporting documentation of growth measurements and evaluation required
    PrescriberPrescribed by or in consultation with an endocrinologist
    Severe Primary IGF-1 Deficiency (PIGF-1D)
    DefinitionSevere Primary IGF-1 Deficiency (PIGF-1D): Diagnosis plus height SDS <= -3.0 and basal IGF-1 SDS <= -3.0 with normal or elevated GH
    Age/prescriberMember >=2 years; prescribed by endocrinologist
    ContinuationAnnual re-evaluation and documentation of increased growth velocity required
    Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
    DefinitionObstructive Sleep Apnea/Hypopnea Syndrome (OSAHS): Diagnosis confirmed by sleep study with >=5 obstructive events/hour plus associated symptoms
    AlternativePrescriber may justify lack of sleep study if not feasible
    PrescriberPrescribed by or in consultation with a neurologist or sleep specialist
    Pseudobulbar Affect (PBA)
    DefinitionPseudobulbar Affect (PBA): Involuntary and inappropriate laughing or crying associated with neurologic conditions (ALS, MS, Alzheimer’s, Parkinson’s, stroke, TBI)
    PrescriberPrescribed by or in consultation with neurologist or psychiatrist
    ExclusionProlonged QT, congenital long QT syndrome, or Torsades de pointes documented by cardiac testing is an exclusion for related products
    Pulmonary arterial hypertension (PAH) criteria definition
    DefinitionPulmonary arterial hypertension (PAH) criteria: WHO Group I with NYHA Class II-IV and hemodynamic confirmation (mean PAP >=25 mm Hg at rest or >30 mm Hg with exertion)
    Diagnostic confirmationRight-heart catheterization or echocardiography required
    PrescriberPrescribed by or in consultation with cardiologist or pulmonologist
    Statin intolerance documentation
    Statin intolerance documentationEvidence of rhabdomyolysis or CK >10x ULN, or AST/ALT >3x ULN, or intolerable symptoms despite trials of two statins
    UseCan be used to document statin intolerance for lipid‑lowering agent authorization
    Required labsCK and liver transaminases documentation expected
    Statin intolerance (dup)
    Statin intolerance criteriaDocumented rhabdomyolysis or CK >10x ULN; myalgia/myositis with two statins; hepatotoxicity AST/ALT >3x ULN; significant liver disease
    PurposeSupports approval pathways where statin therapy cannot be tolerated
    DocumentationClinical notes and labs required to support intolerance claim
    ATTR-CM confirmation
    ATTR-CM confirmationEither TTR mutation, biopsy demonstrating TTR amyloid, or supportive imaging (echo/MRI + scintigraphy) and exclusion of light-chain amyloidosis
    Clinical requirementDocumentation of heart failure history or prior HF hospitalization and NYHA class I-III required
    PrescriberPrescribed by or in consultation with a cardiologist